<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CARBIDOPA, LEVODOPA AND ENTACAPONE- carbidopa, levodopa and entacaponeÂ tablet, film coatedÂ </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use carbidopa, levodopa and entacapone tablets safely and effectively.  See full prescribing information for carbidopa, levodopa and entacapone tablets.<br>Â <br>CARBIDOPA, LEVODOPA and ENTACAPONE tablets, for oral use<br>Initial U.S. Approval: 2003</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa (aromatic amino acid), carbidopa (aromatic amino acid decarboxylation inhibitor), and entacapone (catechol-O-methyltransferase (COMT) inhibitor) is indicated for the treatment of Parkinsonâ€™s disease. </p>
<p class="Highlighta">Carbidopa, levodopa and entacapone tablets are to be used: </p>
<dl>
<dt>â€¢</dt>
<dd>To substitute (with equivalent strengths of each of the three components) for carbidopa/levodopa and entacapone previously administered as individual products (<a href="#ID_646f6e45-8877-4f00-a0ca-097f0e9ebb4d">1</a>)</dd>
<dt>â€¢</dt>
<dd>To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose â€œwearing-offâ€? and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span> (<a href="#ID_646f6e45-8877-4f00-a0ca-097f0e9ebb4d">1</a>)</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>The optimum daily dosage of carbidopa, levodopa and entacapone tablets must be determined by careful titration in each patient (<a href="#ID_4c14fce3-a511-4411-926c-3ea322e9f4c5">2.1</a>)</dd>
<dt>â€¢</dt>
<dd>Individual tablets should not be split or fractionated. Administer only one tablet at each dosing interval (<a href="#ID_0e542b37-884a-4752-8e5b-af6166fea435">2.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<dl>
<dt>Â </dt>
<dd>Each carbidopa, levodopa and entacapone tablet contains a 1:4 ratio of carbidopa to levodopa and 200 mg of entacapone (mg of carbidopa per mg of levodopa per mg of entacapone)</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>12.5 mg per 50 mg per 200 mg</dd>
<dt>â€¢</dt>
<dd>18.75 mg per 75 mg per 200 mg</dd>
<dt>â€¢</dt>
<dd>25 mg per 100 mg per 200 mg</dd>
<dt>â€¢</dt>
<dd>31.25 mg per 125 mg per 200 mg</dd>
<dt>â€¢</dt>
<dd>37.5 mg per 150 mg per 200 mg</dd>
<dt>â€¢</dt>
<dd>50 mg per 200 mg per 200 mg</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Concomitant use of nonselective monoamine oxidase (MAO) inhibitors (<a href="#ID_6410b379-1147-4787-9ae7-7d09f1989ef3">4</a>)</dd>
<dt>â€¢</dt>
<dd>Narrowâ€‘angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (<a href="#ID_6410b379-1147-4787-9ae7-7d09f1989ef3">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>May cause <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep during activities of daily living without apparent warning, and daytime <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (<a href="#ID_c7922561-f847-4818-be4a-c2c1b41717e6">5.1</a>)</dd>
<dt>â€¢</dt>
<dd>May cause <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (<a href="#ID_e16a3ee8-1254-480c-b075-11c1a491461d">5.2</a>)</dd>
<dt>â€¢</dt>
<dd>May cause or exacerbate <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> (<a href="#ID_c5d32ce3-ca07-4527-a14d-645aa13a2593">5.3</a>)</dd>
<dt>â€¢</dt>
<dd>May cause <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and suicidality (<a href="#ID_9bd17067-cecd-4dd6-b69b-05a1cca7365d">5.4</a>)</dd>
<dt>â€¢</dt>
<dd>May cause <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> and/or other <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior (<a href="#ID_6e375e17-13db-4d21-8bc1-b48074c20e03">5.5</a>)</dd>
<dt>â€¢</dt>
<dd>May cause problems with impulse control and compulsive behaviors (<a href="#ID_a8348c0f-3278-4ad7-9b0a-1f67234c3dea">5.6</a>)</dd>
<dt>â€¢</dt>
<dd>Abrupt discontinuation may cause <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> (<a href="#ID_dd7edf28-a08d-42a7-80f7-a015568ad9dd">5.7</a>)</dd>
<dt>â€¢</dt>
<dd>May cause <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and/or drug-induced <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (<a href="#ID_0f5dfc39-db5d-41ce-b0ed-679998452936">5.8</a>)</dd>
<dt>â€¢</dt>
<dd>May cause <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (<a href="#ID_e1a20273-e5d9-4c87-9e18-c82b15c83d96">5.9</a>)</dd>
<dt>â€¢</dt>
<dd>Increased risk of melanoma (<a href="#ID_4533d731-4611-412b-b767-40a54b74e9f3">5.10</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (incidence 3% or higher than placebo incidence) are <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span>, <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">urine discoloration</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (<a href="#ID_65666e85-35ec-4469-8b9a-8b72c5c6aa10">6</a>)  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX)  or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Drugs metabolized by COMT: use with caution (<a href="#ID_751dc726-a2b0-4829-8a23-f47fb40420fe">5.11</a>,<a href="#ID_ef519b57-0bf9-4302-a74c-668e6f4a94cb">7.2</a>)</dd>
<dt>â€¢</dt>
<dd>Anti-hypertensive agents: dose adjustment may be required (<a href="#ID_2af7f26a-7bce-43bb-b129-88f797a6adb2">7.3</a>)</dd>
<dt>â€¢</dt>
<dd>Tricyclic antidepressants: risk of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> reported during concomitant use with carbidopa/levodopa (<a href="#ID_bab534be-4d7a-4306-8426-fc4ed51dcbf7">7.4</a>) </dd>
<dt>â€¢</dt>
<dd>Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of carbidopa, levodopa and entacapone tablets (<a href="#ID_302e4e8e-16c3-485b-982e-630545a292a9">7.5</a>, <a href="#ID_204d7a7f-aae6-4ce4-a35f-44e389a31d6f">7.6</a>, <a href="#ID_77e5b329-ad03-42d1-95de-76d70f118c92">7.7</a>, <a href="#ID_fc6772a5-bdbd-42cd-8820-c8cb49db26f9">7.8</a>, <a href="#ID_af4ce57c-34bc-4698-b175-35fe30c13275">7.9</a>)</dd>
<dt>â€¢</dt>
<dd>Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of carbidopa, levodopa and entacapone tablets may be required (<a href="#ID_b87dd6a6-9d57-4b62-821c-ddda5e0e0dea">7.10</a>)</dd>
<dt>â€¢</dt>
<dd>Drugs metabolized by CYP2C9 (e.g., coumadin): dose adjustment of carbidopa, levodopa and entacapone tablets may be required; monitor INR when initiating carbidopa, levodopa and entacapone tablets in patients on coumadin (<a href="#ID_3c6fa16d-619b-4a8b-8f80-96bfa9f7d5dc">7.11</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy: based on animal data, may cause fetal harm (<a href="#ID_8958a2c8-77fb-4f73-a15a-1670c7258f20">8.1</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Converting Patients from Carbidopa, Levodopa, and Entacapone to Carbidopa, Levodopa and Entacapone Tablets</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Converting Patients from Carbidopa and Levodopa Products to Carbidopa, Levodopa and Entacapone Tablets</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Concomitant Use with Other Anti-Parkinsonâ€™s Disease Drugs</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Decrease or Interruption of Dosing</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Important Administration Instructions</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep During Activities of Daily Living and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Suicidality</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> and/or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span>-Like Behavior</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Impulse Control and/or Compulsive Behaviors</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Withdrawal-Emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span> </a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> </a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Melanoma </a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Interaction with Drugs Metabolized by COMT</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Fibrotic Complications </a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic Ulcer Disease</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 MAO Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drugs Metabolized by Catechol-O-Methyltransferase (COMT)</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Antihypertensive Agents</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Tricyclic Antidepressants</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Dopamine D2 Receptor Antagonists</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Isoniazid</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Phenytoin</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Papaverine</a></h2>
<h2><a href="#section-7.9" class="toc">7.9 Iron Salts</a></h2>
<h2><a href="#section-7.10" class="toc">7.10 Drugs Known to Interfere with Biliary Excretion, Glucuronidation, and Intestinal Beta-glucuronidase </a></h2>
<h2><a href="#section-7.11" class="toc">7.11 Drugs Metabolized via CYP2C9 (e.g., coumadin)</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> or Biliary Obstruction</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1 Signs and Symptoms of Overdosage</a></h2>
<h2><a href="#section-9.2" class="toc">10.2 Management of Overdosage</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.6 Hormone Levels</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_646f6e45-8877-4f00-a0ca-097f0e9ebb4d"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-O-methyltransferase-COMT inhibitor) is indicated for the treatment of Parkinsonâ€™s disease.</p>
<p>Carbidopa, levodopa and entacapone tablets can be used: </p>
<dl>
<dt>â€¢</dt>
<dd>To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products.</dd>
<dt>â€¢</dt>
<dd>To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose â€œwearing-offâ€? and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span>. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_4a27b8aa-c550-495d-a11f-2b86de02117b"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Carbidopa, levodopa and entacapone tablets should be used as a substitute for patients already stabilized on equivalent doses of carbidopa/levodopa and entacapone. However, some patients who have been stabilized on a given dose of carbidopa/levodopa may be treated with carbidopa, levodopa and entacapone tablets if a decision has been made to add entacapone (see below). Therapy should be individualized and adjusted according to the desired therapeutic response.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4c14fce3-a511-4411-926c-3ea322e9f4c5"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Information</h2>
<p class="First">The optimum daily dosage of carbidopa, levodopa and entacapone tablets must be determined by careful titration in each patient. </p>
<p>Clinical experience with daily doses above 1,600 mg of entacapone is limited. The maximum recommended daily dose of carbidopa, levodopa and entacapone tablets depends on the strength used. The maximum number of tablets to be used in a 24-hour period is less with the highest strength (carbidopa, levodopa and entacapone tablets, 50 mg per 200 mg per 200 mg) than with lower strengths (see Table 1). Studies show that peripheral dopa decarboxylase is saturated by carbidopa at approximately 70 mg per day to 100 mg per day. Patients receiving less than this amount of carbidopa are more likely to experience <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<a name="_RefID0EP5AE"></a><table width="100%">
<caption><span>Table 1: Maximum Recommended Dose of Carbidopa, Levodopa and Entacapone Tablets in a 24-hour Period</span></caption>
<col width="41%">
<col width="59%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Carbidopa, Levodopa and Entacapone Tablets Dosage Strength</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Maximum Number of Tablets in a 24-hour Period</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First">12.5 mg per 50 mg per 200 mg,</p>
<p>18.75 mg per 75 mg per 200 mg, </p>
<p>25 mg per 100 mg per 200 mg, </p>
<p>31.25 mg per 125 mg per 200 mg, </p>
<p>37.5 mg per 150 mg per 200 mg</p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">50 mg per 200 mg per 200 mg</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_28c334b1-9cb6-4bac-a0a7-0e913f58a312"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Converting Patients from Carbidopa, Levodopa, and Entacapone to Carbidopa, Levodopa and Entacapone Tablets</h2>
<p class="First">Patients currently treated with entacapone 200 mg with each dose of non-extended release carbidopa/levodopa tablet, can switch to the corresponding strength of carbidopa, levodopa and entacapone tablets containing the same amounts of levodopa and carbidopa. For example, patients receiving one tablet of carbidopa/levodopa 25 mg/100 mg and one tablet of entacapone 200 mg at each administration can switch to a single carbidopa, levodopa and entacapone tablet (containing 25 mg of carbidopa, 100 mg of levodopa and 200 mg of entacapone).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d197f920-848f-447f-84e4-0f699b5ed4d1"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Converting Patients from Carbidopa and Levodopa Products to Carbidopa, Levodopa and Entacapone Tablets</h2>
<p class="First">There is no experience in transferring patients currently treated with extended release formulations of carbidopa/levodopa, or carbidopa/levodopa products that are not combined in a 1:4 ratio of carbidopa to levodopa. </p>
<p>Patients with a history of moderate or severe <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span> or taking more than 600 mg of the levodopa component per day are likely to require a reduction in their daily levodopa dose when entacapone is added. Because dose adjustment of the individual carbidopa or levodopa component is not possible with fixed-dose products, initially titrate patients to a dose that is tolerated and that meets their individual therapeutic need using a separate carbidopa/levodopa tablet (1:4 ratio) plus an entacapone tablet. Once the patientâ€™s individual dose of carbidopa/levodopa plus entacapone dose has been established using two separate tablets; switch the patient to a corresponding single tablet of carbidopa, levodopa and entacapone.  </p>
<p>When less levodopa is required, reduce the total daily dosage of carbidopa/levodopa either by decreasing the strength of carbidopa, levodopa and entacapone tablets at each administration or by decreasing the frequency of administration by extending the time between doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_17903ce8-5fbd-45f0-bf9c-88e29d56fab1"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Concomitant Use with Other Anti-Parkinsonâ€™s Disease Drugs</h2>
<p class="First">Anticholinergic agents, dopamine agonists, monoamine oxidase (MAO) - B inhibitors, amantadine, and other standard drugs for Parkinson's disease may be used concomitantly while carbidopa, levodopa and entacapone tablets are being administered; however, dosage adjustments of the concomitant medication or carbidopa, levodopa and entacapone tablets may be required. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0b6a1361-baa8-4d8c-9fd6-127f01170dac"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Decrease or Interruption of Dosing</h2>
<p class="First">Avoid interruption of carbidopa, levodopa and entacapone tablets dosing because <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span> has been reported in patients who suddenly discontinue or reduce their use of levodopa [<span class="Italics">see <a href="#ID_dd7edf28-a08d-42a7-80f7-a015568ad9dd">Warnings and Precautions (5.7)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0e542b37-884a-4752-8e5b-af6166fea435"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Important Administration Instructions</h2>
<p class="First">Do not split, crush or chew carbidopa, levodopa and entacapone tablets. Administer only one tablet at each dosing interval. All strengths of carbidopa, levodopa and entacapone tablets contain 200 mg of entacapone. Combining multiple tablets or portions of tablets to achieve a higher levodopa dose may lead to an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of entacapone.</p>
<p>Administer carbidopa, levodopa and entacapone tablets with or without food. However, a high-fat, high-calorie meal may delay the absorption of levodopa by about 2 hours [<span class="Italics">see <a href="#ID_4101044e-f5f6-4a04-b9d6-42715d094fbc">Clinical Pharmacology (12.3)</a></span>]<span class="Italics">. </span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_d1deaec5-e0a3-4a4a-ae0e-485625c41482"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Each carbidopa, levodopa and entacapone tablet, provided in 6 single-dose strengths, contains carbidopa and levodopa in a 1:4 ratio and a 200 mg dose of entacapone. Carbidopa, levodopa and entacapone tablets are supplied as filmâ€‘coated tablets for oral administration in the following 6 strengths:</p>
<p>Carbidopa, levodopa and entacapone filmâ€‘coated tablets containing 12.5 mg of carbidopa, 50 mg of levodopa and 200 mg of entacapone. The round, biâ€‘convex shaped tablets are brownishâ€‘ or greyishâ€‘red, unscored, and embossed â€œSTOâ€? over â€œ50â€? on one side of the tablet and plain on the other side.</p>
<p>Carbidopa, levodopa and entacapone filmâ€‘coated tablets containing 18.75 mg of carbidopa, 75 mg of levodopa and 200 mg of entacapone. The oval-shaped tablets are light brownish red, unscored and embossed with code â€œSTOâ€? over â€œ75â€? on one side of the tablet and plain on the other side.</p>
<p>Carbidopa, levodopa and entacapone filmâ€‘coated tablets containing 25 mg of carbidopa, 100 mg of levodopa and 200 mg of entacapone. The ovalâ€‘shaped tablets are brownishâ€‘ or greyishâ€‘red, unscored, and embossed â€œSTOâ€? over â€œ100â€? on one side of the tablet and plain on the other side.</p>
<p>Carbidopa, levodopa and entacapone filmâ€‘coated tablets containing 31.25 mg of carbidopa, 125 mg of levodopa and 200 mg of entacapone. The oval-shaped tablets are light brownish red, unscored and embossed with code â€œSTOâ€? over â€œ125â€? on one side of the tablet and plain on the other side.</p>
<p>Carbidopa, levodopa and entacapone filmâ€‘coated tablets containing 37.5 mg of carbidopa, 150 mg of levodopa and 200 mg of entacapone. The elongatedâ€‘ellipse shaped tablets are brownishâ€‘ or greyishâ€‘red, unscored, and embossed â€œSTOâ€? over â€œ150â€? on one side of the tablet and plain on the other side.</p>
<p>Carbidopa, levodopa and entacapone filmâ€‘coated tablets containing 50 mg of carbidopa, 200 mg of levodopa and 200 mg of entacapone. The oval shaped tablets are dark brownish red, unscored, and embossed â€œSTOâ€? over â€œ200â€? on one side of the tablet and plain on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_6410b379-1147-4787-9ae7-7d09f1989ef3"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Carbidopa, levodopa and entacapone tablets are contraindicated in patients: </p>
<dl>
<dt>â€¢</dt>
<dd>Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). These nonselective MAO inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa, levodopa and entacapone tablets.</dd>
<dt>â€¢</dt>
<dd>With narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_b1138378-998b-4364-b0b3-8994e27af545"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First">The following adverse reactions described in this section are related to at least one of the components of carbidopa, levodopa and entacapone tablets (i.e., levodopa, carbidopa, and/or entacapone) based upon the safety experience in clinical trials (especially pivotal trials) or in postmarketing reports. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c7922561-f847-4818-be4a-c2c1b41717e6"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep During Activities of Daily Living and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></h2>
<p class="First">Patients with Parkinsonâ€™s disease treated with carbidopa, levodopa and entacapone tablets or other carbidopa/levodopa products have reported suddenly <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep without prior warning of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> while engaged in activities of daily living (including the operation of motor vehicles). Some of these episodes resulted in <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span>. Although many of these patients reported <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> while taking entacapone, some did not perceive warning signs, such as excessive <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and believed that they were alert immediately prior to the event. Some of these events have been reported to occur up to one year after initiation of treatment.</p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> was reported in 2% of patients taking entacapone and 0% in placebo in controlled trials. It is reported that <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while engaged in activities of daily living always occurs in a setting of pre-existing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, although patients may not give such a history. For this reason, prescribers should reassess patients for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> especially since some of the events occur well after the start of treatment. Prescribers should also be aware that patients may not acknowledge <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> until directly questioned about <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> during specific activities. Patients who have already experienced <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and/or an episode of sudden sleep onset should not participate in these activities during treatment with carbidopa, levodopa and entacapone tablets.</p>
<p>Before initiating treatment with carbidopa, levodopa and entacapone tablets, advise patients of the potential to develop <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and specifically ask about factors that may increase this risk such as use of concomitant sedating medications and the presence of <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span>. If a patient develops <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">daytime sleepiness</span> or episodes of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep during activities that require active participation (e.g., conversations, eating, etc.), carbidopa, levodopa and entacapone tablets should ordinarily be discontinued [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_0b6a1361-baa8-4d8c-9fd6-127f01170dac">Dosage and Administration (2.5)</a> and <a href="#ID_dd7edf28-a08d-42a7-80f7-a015568ad9dd">Warnings and Precautions (5.7)</a></span>]. If the decision is made to continue carbidopa, levodopa and entacapone tablets, patients should be advised not to drive and to avoid other potentially dangerous activities. There is insufficient information to establish whether dose reduction will eliminate episodes of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while engaged in activities of daily living.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e16a3ee8-1254-480c-b075-11c1a491461d"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></h2>
<p class="First">Reports of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> were generally more frequent in patients in both treatment groups who had had a prior episode of documented <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (although the episodes of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, obtained by history, were themselves not documented with vital sign measurement). <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> are observed in patients treated with drugs that increase central dopaminergic tone including carbidopa, levodopa and entacapone tablets. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c5d32ce3-ca07-4527-a14d-645aa13a2593"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span> (involuntary movements) may occur or be exacerbated at lower dosages and sooner with carbidopa, levodopa and entacapone tablets than with preparations containing only carbidopa and levodopa. The occurrence of <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span> may require dosage reduction.</p>
<p>In pivotal trials, the treatment difference incidence of <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> was 10% and for carbidopa-levodopa plus 200 mg entacapone. Although decreasing the dose of levodopa may ameliorate this side effect, many patients in controlled trials continued to experience frequent <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span> despite a reduction in their dose of levodopa. The treatment difference incidence of study withdrawal for <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> was 1% for carbidopa-levodopa-entacapone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9bd17067-cecd-4dd6-b69b-05a1cca7365d"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Suicidality</h2>
<p class="First">All patients should be observed carefully for the development of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> with concomitant suicidal tendencies. Patients with past or current psychoses should be treated with caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6e375e17-13db-4d21-8bc1-b48074c20e03"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> and/or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span>-Like Behavior</h2>
<p class="First">Dopaminergic therapy in patients with Parkinsonâ€™s disease has been associated with <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> led to drug discontinuation and premature withdrawal from clinical trials in 0.8% and 0% of patients treated with carbidopa, levodopa, entacapone and carbidopa, levodopa, respectively. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> led to hospitalization in 1.0% and 0.3% of patients in the carbidopa, levodopa, entacapone and carbidopa, levodopa, groups, respectively. <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> occurred in 1% of patients treated with carbidopa, levodopa, entacapone and 0% treated with carbidopa, levodopa. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a8348c0f-3278-4ad7-9b0a-1f67234c3dea"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Impulse Control and/or Compulsive Behaviors</h2>
<p class="First">Postmarketing reports suggest that patients treated with anti-Parkinson medications can experience intense urges to gamble, increased sexual urges, intense urges to spend money uncontrollably, and other intense urges. Patients may be unable to control these urges while taking one or more of the medications generally used for the treatment of Parkinsonâ€™s disease and which increase central dopaminergic tone, including entacapone taken with levodopa and carbidopa. In some cases, although not all, these urges were reported to have stopped when the dose of anti-Parkinson medications was reduced or discontinued. Because patients may not recognize these behaviors as abnormal it is important for prescribers to specifically ask patients or their caregivers about the development of new or increased <span class="product-label-link" type="condition" conceptid="4023166" conceptname="Gambling">gambling</span> urges, sexual urges, uncontrolled spending or other urges while being treated with entacapone. Physicians should consider dose reduction or stopping carbidopa, levodopa and entacapone tablets if a patient develops such urges while taking carbidopa, levodopa and entacapone tablets [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_0b6a1361-baa8-4d8c-9fd6-127f01170dac">Dosage and Administration (2.5)</a>, <a href="#ID_dd7edf28-a08d-42a7-80f7-a015568ad9dd">Warnings and Precautions (5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_dd7edf28-a08d-42a7-80f7-a015568ad9dd"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Withdrawal-Emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span> </h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> resembling <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. However, in some cases, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> were reported after initiation of treatment with entacapone. <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> are uncommon but they may be lifeâ€‘threatening with a variety of features, including <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>/<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>/<span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, involuntary movements, altered consciousness/<span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic dysfunction</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, hyperâ€‘ or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and abnormal laboratory findings (e.g., creatine phosphokinase elevation, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>, and increased serum myoglobin). </p>
<p>If a patient needs to discontinue or reduce their daily dose of carbidopa, levodopa and entacapone tablets, the dose should be decreased slowly, with supervision from a health care provider [<span class="Italics">see <a href="#ID_0b6a1361-baa8-4d8c-9fd6-127f01170dac">Dosage and Administration (2.5)</a></span>]. Specific methods for tapering entacapone have not been systematically evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0f5dfc39-db5d-41ce-b0ed-679998452936"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></h2>
<p class="First">In clinical trials of entacapone, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> developed in 60 of 603 (10.0%) and 16 of 400 (4.0%) of patients treated with 200 mg of entacapone or placebo in combination with levodopa and dopa decarboxylase inhibitor, respectively. In patients treated with entacapone, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was generally mild to moderate in severity (8.6%) but was regarded as severe in 1.3%. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> resulted in withdrawal in 10 of 603 (1.7%) patients, 7 (1.2%) with mild and moderate <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and 3 (0.5%) with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> generally resolved after discontinuation of entacapone. Two patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> were hospitalized. Typically, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> presents within 4 to 12 weeks after entacapone is started, but it may appear as early as the first week and as late as many months after the initiation of treatment. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> may be associated with <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p>Postmarketing experience has shown that <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may be a sign of drug-induced microscopic <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, primarily <span class="product-label-link" type="condition" conceptid="4151446" conceptname="Lymphocytic-plasmacytic colitis">lymphocytic colitis</span>. In these cases <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> has usually been moderate to severe, watery and non-bloody, at times associated with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. In the majority of cases, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and other <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>-related symptoms resolved or significantly improved when entacapone treatment was stopped. In some patients with biopsy confirmed <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> had resolved or significantly improved after discontinuation of entacapone but recurred after retreatment with entacapone.</p>
<p>If prolonged <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is suspected to be related to carbidopa, levodopa and entacapone tablets, the drug should be discontinued and appropriate medical therapy considered. If the cause of prolonged <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> remains unclear or continues after stopping entacapone, then further diagnostic investigations including colonoscopy and biopsies should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e1a20273-e5d9-4c87-9e18-c82b15c83d96"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> </h2>
<p class="First">Cases of severe <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported with entacapone when used in combination with carbidopa and levodopa. Severe prolonged motor activity including <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> may possibly account for <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>. Most of the cases were manifested by <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> and increased values of creatine phosphokinase (CPK) and myoglobin. Some of the reactions also included <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and/or alteration of consciousness. It is also possible that <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> may be a result of the syndrome described in Withdrawal-Emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>[<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_dd7edf28-a08d-42a7-80f7-a015568ad9dd">Warnings and Precautions (5.7)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4533d731-4611-412b-b767-40a54b74e9f3"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Melanoma </h2>
<p class="First">Epidemiological studies have shown that patients with Parkinsonâ€™s disease have a higher risk (2- to approximately 6-fold higher) of developing melanoma than the general population. Whether the increased risk observed was due to Parkinsonâ€™s disease or other factors, such as drugs used to treat Parkinsonâ€™s disease, is unclear.</p>
<p>For the reasons stated above, patients and providers are advised to monitor for melanomas frequently and on a regular basis when using carbidopa, levodopa and entacapone tablets, for any indication. Ideally, periodic skin examination should be performed by appropriately qualified individuals (e.g., dermatologists).  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_751dc726-a2b0-4829-8a23-f47fb40420fe"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Interaction with Drugs Metabolized by COMT</h2>
<p class="First">Drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alphaâ€‘methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction may result in increased heart rate, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, and/or <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6f4513db-2140-467d-93b9-317a32555fdb"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Fibrotic Complications </h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span>, pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, and <span class="product-label-link" type="condition" conceptid="4050884" conceptname="Pleural plaque">pleural thickening</span> have been reported in some patients treated with ergot derived dopaminergic agents. These complications may resolve when the drug is discontinued, but complete resolution does not always occur. Although these adverse reactions may be related to the ergoline structure of these compounds, a possible causal role of nonergot derived drugs (e.g., entacapone, levodopa), which increase dopaminergic activity, has also been considered. The expected incidence of fibrotic complications is so low that even if entacapone caused these complications at rates similar to those attributable to other dopaminergic therapies, it is unlikely that it would have been detected in a cohort of the size exposed to entacapone during its clinical development. Four cases of <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span> have been reported during clinical development of entacapone; 3 of these patients were also treated with pergolide and 1 with bromocriptine. The duration of treatment with entacapone ranged from 7 months to 17 months.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bf58a973-4e3e-440a-90dd-2e2d4fa1a982"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic Ulcer Disease</span></h2>
<p class="First">As with levodopa, treatment with carbidopa, levodopa and entacapone tablets may increase the possibility of <span class="product-label-link" type="condition" conceptid="4291649" conceptname="Upper gastrointestinal hemorrhage">upper gastrointestinal hemorrhage</span> in patients with a history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6e4721d0-242a-41e6-9848-28bad994c95b"></a><a name="section-5.14"></a><p></p>
<h2>5.14 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be treated with caution [see <span class="Italics"><a href="#ID_4101044e-f5f6-4a04-b9d6-42715d094fbc">Clinical Pharmacology (12.3)</a></span>]<span class="Italics">.</span> As with levodopa, periodic evaluation of hepatic function is recommended during extended therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9858cf8d-3b03-40db-ad5a-753dd53be9ec"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Laboratory Tests</h2>
<p class="First">Abnormalities in laboratory tests may include elevations of liver function tests such as alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (AST), SGPT (ALT), lactic dehydrogenase, and bilirubin. Abnormalities in blood urea nitrogen and positive Coombs test have also been reported. Commonly, levels of blood urea nitrogen, creatinine, and uric acid are lower during administration of carbidopa, levodopa and entacapone tablets than with levodopa.</p>
<p>Carbidopa, levodopa and entacapone tablets may cause a falseâ€‘positive reaction for urinary <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketone bodies</span> when a test tape is used for determination of <span class="product-label-link" type="condition" conceptid="4171926" conceptname="Ketonuria">ketonuria</span>. This reaction will not be altered by boiling the urine specimen. Falseâ€‘negative tests may result with the use of glucoseâ€‘oxidase methods of testing for glucosuria.</p>
<p>Cases of falsely diagnosed <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> in patients on carbidopa/levodopa therapy have been reported very rarely. Caution should be exercised when interpreting the plasma and urine levels of catecholamines and their metabolites in patients on carbidopa/levodopa therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_65666e85-35ec-4469-8b9a-8b72c5c6aa10"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in more detail in the Warnings and Precautions sections of labeling:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep During Activities of Daily Living and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_c7922561-f847-4818-be4a-c2c1b41717e6">Warnings and Precautions (5.1)</a></span>]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_e16a3ee8-1254-480c-b075-11c1a491461d">Warnings and Precautions (5.2)</a></span>]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span> [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_c5d32ce3-ca07-4527-a14d-645aa13a2593">Warnings and Precautions (5.3)</a></span>]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and suicidality [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_9bd17067-cecd-4dd6-b69b-05a1cca7365d">Warnings and Precautions (5.4)</a></span>]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>/<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span>-Like Behavior [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_6e375e17-13db-4d21-8bc1-b48074c20e03">Warnings and Precautions (5.5)</a></span>]</dd>
<dt>â€¢</dt>
<dd>Impulse Control and/or Compulsive Behaviors [<span class="Italics">seeÂ <a href="#ID_a8348c0f-3278-4ad7-9b0a-1f67234c3dea">Warnings and Precautions (5.6)</a></span>]</dd>
<dt>â€¢</dt>
<dd>Withdrawal-Emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span> [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_dd7edf28-a08d-42a7-80f7-a015568ad9dd">Warnings and Precautions (5.7)</a></span>]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span> [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_0f5dfc39-db5d-41ce-b0ed-679998452936">Warnings and Precautions (5.8)</a></span>]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_e1a20273-e5d9-4c87-9e18-c82b15c83d96">Warnings and Precautions (5.9)</a></span>]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic Ulcer Disease</span> [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_bf58a973-4e3e-440a-90dd-2e2d4fa1a982">Warnings and Precautions (5.13)</a></span>]</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7714296c-b83c-4a74-baf7-5b232b8c5c27"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, the incidence of adverse reactions (number of unique patients experiencing an adverse reaction associated with treatment/total number of patients treated) observed in the clinical trials of a drug cannot be directly compared to the incidence of adverse reactions in the clinical trials of another drug and may not reflect the incidence of adverse reactions observed in clinical practice. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8e9bb264-7199-4139-a002-152144fb0c47"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Entacapone</span></span></h3>
<p class="First">The most commonly observed adverse reactions (incidence at least 3% greater than placebo incidence) in the doubleâ€‘blind, carbidopa-levodopa-placeboâ€‘controlled trials of entacapone (N=1,003 patients) associated with the use of carbidopa-levodopa-entacapone alone and not seen at an equivalent frequency among the placeboâ€‘treated patients were: <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">urine discoloration</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>. </p>
<p>The treatment difference incidence for premature study discontinuation for entacapone with levodopa and dopa decarboxylase inhibitor in the doubleâ€‘blind, placeboâ€‘controlled trials was 5%. The treatment difference incidence for the most frequent causes of study discontinuation was 2% for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and 1% for other specific adverse reactions including psychiatric reasons, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>/ <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_db2149c2-3271-47ef-b3ce-9820b05803c5"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Adverse Reaction Incidence in Controlled Clinical Studies of Entacapone</span></span></h3>
<p class="First">Table 2 lists treatment emergent adverse reactions that occurred in at least 1% of patients treated with carbidopa/levodopa and 200 mg of entacapone who participated in the double-blind, placebo-controlled studies, and that were numerically more common in this group than in the carbidopa/levodopa plus placebo group. In these studies, either entacapone or placebo was added to carbidopa/levodopa (or benserazide/levodopa). </p>
<a name="_RefID0ENYAG"></a><table width="100%">
<caption><span>Table 2: Summary of Patients With Adverse Reactions After Start of Trial Drug Administration At Least 1% in Entacapone Group and Greater Than Placebo</span></caption>
<col width="2%">
<col width="33%">
<col width="32%">
<col width="32%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" colspan="2"><p class="First"><span class="Bold">SYSTEM ORGAN CLASS</span></p></td>
<td class="Toprule" align="center">
<p class="First">Carbidopa/levodopa plus</p>
<p>Entacapone</p>
</td>
<td class="Toprule" align="center"><p class="First">Carbidopa/levodopa plus Placebo</p></td>
</tr>
<tr>
<td></td>
<td><p class="First">Preferred Term</p></td>
<td align="center"><p class="First">(n=603)</p></td>
<td align="center"><p class="First">(n=400)</p></td>
</tr>
<tr>
<td class="Botrule" colspan="2"></td>
<td class="Botrule" align="center"><p class="First">% of patients</p></td>
<td class="Botrule" align="center"><p class="First">% of patients</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold">SKIN AND APPENDAGES DISORDERS</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating Increased</span></p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold">MUSCULOSKELETAL SYSTEM DISORDERS</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold">CENTRAL AND PERIPHERAL <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">NERVOUS SYSTEM DISORDERS</span></span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span></p></td>
<td align="center"><p class="First">25</p></td>
<td align="center"><p class="First">15</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">Hyperkinesia</span></p></td>
<td align="center"><p class="First">10</p></td>
<td align="center"><p class="First">5</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">Hypokinesia</span></p></td>
<td align="center"><p class="First">9</p></td>
<td align="center"><p class="First">8</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td align="center"><p class="First">8</p></td>
<td align="center"><p class="First">6</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold">SPECIAL SENSES, OTHER DISORDERS</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Perversion</span></p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold">PSYCHIATRIC DISORDERS</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold">GASTROINTESTINAL SYSTEM DISORDERS</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center"><p class="First">14</p></td>
<td align="center"><p class="First">8</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="center"><p class="First">10</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td align="center"><p class="First">8</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="center"><p class="First">4</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Mouth Dry</span></p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span></p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> NOS</p></td>
<td align="center"><p class="First">1</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">RESPIRATORY SYSTEM DISORDERS</span></span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td align="center"><p class="First">3</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold">PLATELET, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> AND <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">CLOTTING DISORDERS</span></span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span></p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold">URINARY SYSTEM DISORDERS</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">Urine Discoloration</span></p></td>
<td align="center"><p class="First">10</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold">BODY AS A WHOLE</span>â€‘<span class="Bold">GENERAL DISORDERS</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td></td>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td align="center"><p class="First">2</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td colspan="2"><p class="First"><span class="Bold">RESISTANCE MECHANISM DISORDERS</span></p></td>
<td></td>
<td></td>
</tr>
<tr class="Last">
<td class="Botrule"></td>
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">Infection Bacterial</span></p></td>
<td class="Botrule" align="center"><p class="First">1</p></td>
<td class="Botrule" align="center"><p class="First">0</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ba4ae0b2-e299-409c-bc30-f1323e2801be"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following spontaneous reports of adverse events temporally associated with entacapone or carbidopa, levodopa and entacapone tablets have been identified since market introduction and are not listed in Table 2. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish causal relationship to entacapone or carbidopa, levodopa and entacapone tablets exposure.</p>
<p><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> with mainly cholestatic features has been reported.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ad237af1-f24b-40a3-8b1a-d6cb678e6d53"></a><a name="section-6.2.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Effects of Gender and Age on Adverse Reactions</span></span></h3>
<p class="First">No differences were noted in the rate of adverse reactions attributable to entacapone alone by age or gender. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_640e53f5-d985-47a1-a223-67384f23fa6c"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7a8eb2ca-fe9d-440d-989e-583678c2f59f"></a><a name="section-7.1"></a><p></p>
<h2>7.1 MAO Inhibitors</h2>
<p class="First">Patients receiving nonselective MAO inhibitors and carbidopa, levodopa and entacapone may be at risk of increased adrenergic tone. Therefore, the use of carbidopa, levodopa and entacapone tablets is contraindicated in patients receiving nonselective MAO inhibitors [<span class="Italics">see <a href="#ID_6410b379-1147-4787-9ae7-7d09f1989ef3">Contraindications (4)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ef519b57-0bf9-4302-a74c-668e6f4a94cb"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drugs Metabolized by Catechol-O-Methyltransferase (COMT)</h2>
<p class="First">Drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alphaâ€‘methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction may result in increased heart rates, possibly <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and excessive changes in blood pressure [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_751dc726-a2b0-4829-8a23-f47fb40420fe">Warnings and Precautions (5.11)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2af7f26a-7bce-43bb-b129-88f797a6adb2"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Antihypertensive Agents</h2>
<p class="First">Symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. When starting therapy with carbidopa, levodopa and entacapone tablets, dosage adjustment of antihypertensive drug may be required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bab534be-4d7a-4306-8426-fc4ed51dcbf7"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Tricyclic Antidepressants</h2>
<p class="First">There have been reports of adverse reactions, including <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, resulting from the concomitant use of tricyclic antidepressants and carbidopa/levodopa. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_302e4e8e-16c3-485b-982e-630545a292a9"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Dopamine D2 Receptor Antagonists</h2>
<p class="First">Dopamine D2 receptor antagonists (e.g., metoclopramide, phenothiazines, butyrophenones, risperidone) may reduce the therapeutic effects of levodopa. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_204d7a7f-aae6-4ce4-a35f-44e389a31d6f"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Isoniazid</h2>
<p class="First">Isoniazid may reduce the therapeutic effects of levodopa, a dose increase may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_77e5b329-ad03-42d1-95de-76d70f118c92"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Phenytoin</h2>
<p class="First">The beneficial effects of levodopa in Parkinsonâ€™s disease have been reported to be reversed by phenytoin. Patients taking phenytoin with carbidopa/levodopa should be carefully observed for loss of therapeutic response. Carbidopa, levodopa and entacapone tablets dosage should be increased as clinically needed in patients receiving phenytoin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fc6772a5-bdbd-42cd-8820-c8cb49db26f9"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Papaverine</h2>
<p class="First">The beneficial effects of levodopa in Parkinsonâ€™s disease have been reported to be reversed by papaverine. Patients taking papaverine with carbidopa/levodopa should be carefully observed for loss of therapeutic response. Carbidopa, levodopa and entacapone tablets dosage should be increased as clinically needed in patients receiving papaverine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_af4ce57c-34bc-4698-b175-35fe30c13275"></a><a name="section-7.9"></a><p></p>
<h2>7.9 Iron Salts</h2>
<p class="First">Iron salts or multi vitamins containing iron salts should be coadministered with caution. Iron salts can form chelates with levodopa, carbidopa and entacapone and consequently reduce bioavailability of levodopa, carbidopa and entacapone. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b87dd6a6-9d57-4b62-821c-ddda5e0e0dea"></a><a name="section-7.10"></a><p></p>
<h2>7.10 Drugs Known to Interfere with Biliary Excretion, Glucuronidation, and Intestinal Beta-glucuronidase </h2>
<p class="First">As most entacapone excretion is via the bile, caution should be exercised when drugs known to interfere with biliary excretion, glucuronidation, and intestinal betaâ€‘glucuronidase are given concurrently with entacapone. These include probenecid, cholestyramine, and some antibiotics (e.g., erythromycin, rifampicin, ampicillin and chloramphenicol).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3c6fa16d-619b-4a8b-8f80-96bfa9f7d5dc"></a><a name="section-7.11"></a><p></p>
<h2>7.11 Drugs Metabolized via CYP2C9 (e.g., coumadin)</h2>
<p class="First">The dosage of carbidopa, levodopa and entacapone tablets should be adjusted as clinically needed in patients using other drugs metabolized via CYP2C9. An interaction study in healthy volunteers, entacapone increased the AUC of R-warfarin on average by 18%, and the INR values on average by 13%. Cases of increased INR in patients concomitantly using warfarin have been reported during the post-approval use of entacapone. Thus, monitoring of INR is recommended when carbidopa, levodopa and entacapone tablets treatment is initiated for patients receiving warfarin.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_423cffb3-1612-4fa7-8197-11aade933182"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_8958a2c8-77fb-4f73-a15a-1670c7258f20"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_89b90cbd-549c-489d-8bc3-6fb1b91b3fde"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">Pregnancy Category C </span></h3>
<p class="First">There are no adequate and well-controlled studies in pregnant women. It has been reported from individual cases that levodopa crosses the human placental barrier, enters the fetus, and is metabolized. In animals, administration of carbidopa-levodopa or entacapone during pregnancy was associated with developmental toxicity, including increased incidences of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. Carbidopa, levodopa and entacapone tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>In nonclinical studies in which carbidopa-levodopa was administered to pregnant animals, increased incidences of visceral and skeletal malformations were observed in rabbits at all doses and ratios of carbidopa-levodopa tested, which ranged from 10 times (carbidopa)-5 times (levodopa) to 20 times (carbidopa)-10 times (levodopa) the maximum recommended human dose (MRHD) of 1,600 mg/day. In rats, there was a decrease in the number of live pups delivered by dams receiving approximately two times (carbidopa)-five times (levodopa) the MRHD throughout organogenesis. No effects on malformation frequencies were observed in mice receiving up to 20 times the MRHD of carbidopa-levodopa.</p>
<p>In embryo-fetal development studies of entacapone, pregnant animals received doses of up to 1,000 mg/kg/day (rats) or 300 mg/kg/day (rabbits) throughout organogenesis. Increased incidences of fetal variations were evident in litters from rats treated with the highest dose, in the absence of overt signs of maternal toxicity. The maternal plasma entacapone exposure (AUC) associated with this dose was approximately 34 times that in humans at the MRHD. Increased frequencies of abortions and late/total resorptions and decreased fetal weights were observed in the litters of rabbits treated with maternally toxic doses of 100 mg/kg/day (plasma AUCs les than that in humans at the MRHD) or greater. There were no increases in malformation rates in these studies.</p>
<p>When entacapone was administered to female rats prior to mating and during early gestation, an increased incidence of fetal eye anomalies (macrophthalmia, <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>, <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>) was observed in the litters of dams treated with doses of 160 mg/kg/day (plasma AUCs seven times that in humans at the MRHD) or greater, in the absence of maternal toxicity. Administration of up to 700 mg/kg/day (plasma AUCs 28 times that in humans at the MRHD) to rats during the latter part of gestation and throughout lactation produced no evidence of developmental impairment in the offspring.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_1b1ca39d-443d-4a54-a93c-e89674196465"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Carbidopa and entacapone are excreted in rat milk. It is not known whether entacapone, carbidopa, or levodopa is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when carbidopa, levodopa and entacapone tablets are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_317b36cd-7648-4692-9b2f-b224df199d19"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_dac5fd87-62a1-49a1-a13a-88869b9459cc"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects in clinical studies of carbidopa, levodopa and entacapone tablets, 43.8% were 65 years old and over, while 7.2% were 75 years old and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients; however, greater sensitivity of some older individuals cannot be excluded.</p>
<p>Carbidopa, levodopa and entacapone tablets have not been studied in Parkinsonâ€™s disease patients or in healthy volunteers older than 75 years [<span class="Italics">see <a href="#ID_4101044e-f5f6-4a04-b9d6-42715d094fbc">Clinical Pharmacology (12.3)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f01eedbb-efce-49f7-8169-52b3dcd14156"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> does not affect pharmacokinetics of entacapone. There are no studies on the pharmacokinetics of levodopa and carbidopa in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see <a href="#ID_4101044e-f5f6-4a04-b9d6-42715d094fbc">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8b4d7010-f4c4-47b7-989f-7fb2d6112742"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> or Biliary Obstruction</h2>
<p class="First">There are no studies on the pharmacokinetics of carbidopa and levodopa in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Carbidopa, levodopa and entacapone tablets should be administered cautiously to patients with biliary obstruction or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> since biliary excretion appears to be the major route of excretion of entacapone and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> had a significant effect on the pharmacokinetics of entacapone when 200 mg entacapone was administered alone [<span class="Italics">see <a href="#ID_4101044e-f5f6-4a04-b9d6-42715d094fbc">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_7544a2f1-f022-4dd5-beb5-e4bac1cddfca"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9ecfe58d-0ca6-4f7c-8e7e-d10ddbe3b977"></a><a name="section-9.1"></a><p></p>
<h2>10.1 Signs and Symptoms of Overdosage</h2>
<p class="First">There are very few cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with levodopa reported in the published literature. Based on the available information, the acute symptoms of levodopa and dopa decarboxylase inhibitor <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> can be expected to arise from dopaminergic overstimulation. Doses of a few grams may result in CNS disturbances, with an increasing likelihood of cardiovascular disturbance (e.g., <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) and more severe psychiatric problems at higher doses. An isolated report of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> and another of transient <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> suggest that levodopa <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may give rise to systemic complications, secondary to dopaminergic overstimulation.</p>
<p>COMT inhibition by entacapone treatment is doseâ€‘dependent. A massive <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of entacapone may theoretically produce a 100% inhibition of the COMT enzyme in people, thereby preventing the Oâ€‘methylation of endogenous and exogenous catechols.</p>
<p>In clinical trials, the highest single dose of entacapone administered to humans was 800 mg, resulting in a plasma concentration of 14.1 mcg per mL. The highest daily dose given to humans was 2,400 mg, administered in one study as 400 mg six times daily with carbidopa/levodopa for 14 days in 15 Parkinsonâ€™s disease patients, and in another study as 800 mg three times daily for 7 days in 8 healthy volunteers. At this daily dose, the peak plasma concentrations of entacapone averaged 2.0 mcg per mL (at 45 min, compared to 1.0 mcg per mL and 1.2 mcg per mL with 200 mg entacapone at 45 min.). <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> were the most commonly observed adverse events during this study. Daily doses as high as 2,000 mg entacapone have been administered as 200 mg 10 times daily with carbidopa/levodopa or benserazide/levodopa for at least 1 year in 10 patients, for at least 2 years in 8 patients and for at least 3 years in 7 patients. Overall, however, clinical experience with daily doses above 1,600 mg is limited.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4960daf5-ff21-46a5-bae7-4e6348f66fbf"></a><a name="section-9.2"></a><p></p>
<h2>10.2 Management of Overdosage</h2>
<p class="First">Hospitalization is advised, and general supportive measures should be employed, along with immediate gastric lavage and repeated doses of charcoal over time. This may hasten the elimination of entacapone in particular, by decreasing its absorption and reabsorption from the GI tract. Intravenous fluids should be administered judiciously and an adequate airway maintained.</p>
<p>Respiratory, circulatory and renal function should be monitored and appropriate supportive measures employed. Electrocardiographic monitoring should be instituted and the patient carefully observed for the development of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>; if required, appropriate antiarrhythmic therapy should be given. The possibility that the patient may have taken other drugs, increasing the risk of drug interactions (especially catecholâ€‘structured drugs) should be taken into consideration. To date, no experience has been reported with dialysis; hence, its value in overdosage is not known. Hemodialysis or hemoperfusion is unlikely to reduce entacapone levels due to its high binding to plasma proteins.</p>
<p>Pyridoxine is not effective in reversing the actions of carbidopa, levodopa and entacapone tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_6780f078-95a7-48fe-8558-3104fe437d08"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Carbidopa, levodopa and entacapone tablets are a combination of carbidopa, levodopa, and entacapone for the treatment of Parkinsonâ€™s disease.</p>
<p>Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as (-)-L-(Î±-hydrazino-(Î±-methyl-Î²-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its empirical formula is C<span class="Sub">10</span>H<span class="Sub">14</span>N<span class="Sub">2</span>O<span class="Sub">4</span>â€¢H<span class="Sub">2</span>O, and its structural formula is:</p>
<div class="Figure">
<a name="id-1670938618"></a><img alt="Carbidopa Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4a535af2-16fc-4fdf-92ec-7941ef23a63a&amp;name=image-01.jpg">
</div>
<p>Tablet content is expressed in terms of anhydrous carbidopa, which has a molecular weight of 226.3.</p>
<p>Levodopa, an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (-)-L-Î±-amino-Î²-(3,4-dihydroxybenzene) propanoic acid. Its empirical formula is C<span class="Sub">9</span>H<span class="Sub">11</span>NO<span class="Sub">4</span>, and its structural formula is:</p>
<div class="Figure">
<a name="id-1233612497"></a><img alt="Levodopa Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4a535af2-16fc-4fdf-92ec-7941ef23a63a&amp;name=image-02.jpg">
</div>
<p>Entacapone, a COMT inhibitor, is a nitroâ€‘catecholâ€‘structured compound with a molecular weight of 305.3. The chemical name of entacapone is (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide. Its empirical formula is C<span class="Sub">14</span>H<span class="Sub">15</span>N<span class="Sub">3</span>O<span class="Sub">5</span> and its structural formula is:</p>
<div class="Figure">
<a name="id-1957707834"></a><img alt="Entacapone Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4a535af2-16fc-4fdf-92ec-7941ef23a63a&amp;name=image-03.jpg">
</div>
<p>Carbidopa, levodopa and entacapone is supplied as tablets in 6 strengths: </p>
<p>Carbidopa, levodopa and entacapone tablets: 12.5 mg of carbidopa, 50 mg of levodopa and 200 mg of entacapone</p>
<p>Carbidopa, levodopa and entacapone tablets: 18.75 mg of carbidopa, 75 mg of levodopa and 200 mg of entacapone</p>
<p>Carbidopa, levodopa and entacapone tablets: 25 mg of carbidopa, 100 mg of levodopa and 200 mg of entacapone </p>
<p>Carbidopa, levodopa and entacapone tablets: 31.25 mg of carbidopa, 125 mg of levodopa and 200 mg of entacapone </p>
<p>Carbidopa, levodopa and entacapone tablets: 37.5 mg of carbidopa, 150 mg of levodopa and 200 mg of entacapone </p>
<p>Carbidopa, levodopa and entacapone tablets: 50 mg of carbidopa, 200 mg of levodopa and 200 mg of entacapone.</p>
<p><span class="Italics">Inactive Ingredients:</span> corn starch, croscarmellose sodium, glycerol 85%, hypromellose, magnesium stearate, mannitol, polysorbate 80, povidone, sucrose, red iron oxide, and titanium dioxide. Tablets containing 12.5 mg of carbidopa, 50 mg of levodopa and 200 mg of entacapone, tablets containing 25 mg of carbidopa, 100 mg of levodopa and 200 mg of entacapone and tablets containing 37.5 mg of carbidopa, 150 mg of levodopa and 200 mg of entacapone also contain yellow iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_f7b74cb8-2d76-40ad-94f4-727cfb33906e"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_4212f46a-3791-4118-9d76-c7dda017e56a"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4fce4694-1059-424b-9110-31306e3abdba"></a><a name="section-11.1.1"></a><p></p>
<h3><span class="Bold"><span class="Italics">Levodopa</span></span></h3>
<p class="First">Current evidence indicates that symptoms of Parkinsonâ€™s disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinsonâ€™s disease because it does not cross the bloodâ€‘brain barrier. However, levodopa the metabolic precursor of dopamine, does cross the bloodâ€‘brain barrier, and is presumably converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves the symptoms of Parkinsonâ€™s disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a2efbc13-c3c6-4fdb-b64a-c22bcf8214d8"></a><a name="section-11.1.2"></a><p></p>
<h3><span class="Bold"><span class="Italics">Carbidopa</span></span></h3>
<p class="First">When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_897afb54-7d1a-408b-86b0-d723d41bb82b"></a><a name="section-11.1.3"></a><p></p>
<h3><span class="Bold"><span class="Italics">Entacapone</span></span></h3>
<p class="First">Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT).</p>
<p>COMT catalyzes the transfer of the methyl group of Sâ€‘adenosylâ€‘Lâ€‘methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include DOPA, catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. When decarboxylation of levodopa is prevented by carbidopa, COMT becomes the major metabolizing enzyme for levodopa, catalyzing its metabolism to 3â€‘methoxyâ€‘4â€‘hydroxyâ€‘Lâ€‘phenylalanine (3â€‘OMD).</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_4101044e-f5f6-4a04-b9d6-42715d094fbc"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of carbidopa, levodopa and entacapone tablets has been studied in healthy subjects (age 45 years to 75 years). Overall, following administration of corresponding doses of levodopa, carbidopa and entacapone as carbidopa, levodopa and entacapone tablets or as carbidopa and levodopa product plus entacapone tablets, the mean plasma concentrations of levodopa, carbidopa, and entacapone are comparable.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f4a24a32-09b3-4cc3-8206-48f36dd7a6e9"></a><a name="section-11.2.1"></a><p></p>
<h3><span class="Bold"><span class="Underline">Absorption and Distribution</span></span></h3>
<p class="First">Both levodopa and entacapone are rapidly absorbed and eliminated, and their distribution volume is moderately small. Carbidopa is absorbed and eliminated slightly more slowly compared with levodopa and entacapone. There are substantial interâ€‘ and intraâ€‘individual variations in the absorption of levodopa, carbidopa and entacapone, particularly concerning its C<span class="Sub">max</span>.</p>
<p>The food-effect on the carbidopa, levodopa and entacapone tablets has not been evaluated. Because levodopa competes with certain amino acids for transport across the gut wall, the absorption of levodopa may be impaired in some patients after eating a high protein meal. Meals rich in large neutral amino acids may delay and reduce the absorption of levodopa [<span class="Italics">see <a href="#ID_87a2c827-6874-4f85-817a-9e6e7aed88a4">Patient Counseling Information (17)</a></span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5017a628-c280-4ef3-a0bc-b796d747bf3e"></a><a name="section-11.2.1.1"></a><p></p>
<h4><span class="Bold">Levodopa</span></h4>
<p class="First">The pharmacokinetic properties of levodopa following the administration of single-dose carbidopa, levodopa and entacapone tablets are summarized in Table 3.</p>
<p>Table 3: Pharmacokinetic Characteristics of Levodopa with Different Tablet Strengths of Carbidopa, Levodopa and Entacapone Tablets (mean Â± SD)</p>
<table width="100%">
<col width="35%">
<col width="22%">
<col width="22%">
<col width="22%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">AUC<span class="Sub">0</span></span>â€‘<span class="Bold"><span class="Sub">âˆž</span></span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">T<span class="Sub">max</span></span></p></td>
</tr>
<tr>
<td class="Botrule"><p class="First"><span class="Bold">Tablet Strength</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(nanogramÂ·h per mL)</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(nanogram per mL)</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(h)</span></p></td>
</tr>
<tr>
<td><p class="First">12.5 mg per 50 mg per 200 mg</p></td>
<td align="center"><p class="First">1,040 Â± 314</p></td>
<td align="center"><p class="First">470 Â± 154</p></td>
<td align="center"><p class="First">1.1 Â± 0.5</p></td>
</tr>
<tr>
<td><p class="First">25 mg per 100 mg per 200 mg</p></td>
<td align="center"><p class="First">2,910 Â± 715</p></td>
<td align="center"><p class="First">975 Â± 247</p></td>
<td align="center"><p class="First">1.4 Â± 0.6</p></td>
</tr>
<tr>
<td><p class="First">37.5 mg per 150 mg per 200 mg</p></td>
<td align="center"><p class="First">3,770 Â± 1,120</p></td>
<td align="center"><p class="First">1,270 Â± 329</p></td>
<td align="center"><p class="First">1.5 Â± 0.9</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">50 mg per 200 mg per 200 mg</p></td>
<td class="Botrule" align="center"><p class="First">6,115 Â± 1,536</p></td>
<td class="Botrule" align="center"><p class="First">1,859 Â± 455</p></td>
<td class="Botrule" align="center"><p class="First">1.76 Â± 0.7</p></td>
</tr>
</tbody>
</table>
<p>Levodopa is bound to plasma protein only to a minor extent (about 10% to 30%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6e824617-8b71-4e5f-bfd4-776936543458"></a><a name="section-11.2.1.2"></a><p></p>
<h4><span class="Bold">Carbidopa</span></h4>
<p class="First">Following administration of carbidopa, levodopa and entacapone tablets as a single dose to healthy male and female subjects, the peak concentration of carbidopa was reached within 2.5 hours to 3.4 hours on average. The mean C<span class="Sub">max</span> ranged from about 40 nanogram per mL to 225 nanogram per mL and the mean AUC from 170 nanogramâ€¢h per mL to 1,200 nanogramâ€¢h per mL, with different carbidopa, levodopa and entacapone tablets strengths providing 12.5 mg, 25 mg, 37.5 mg, or 50 mg of carbidopa.</p>
<p>Carbidopa is approximately 36% bound to plasma protein.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3d07831a-8542-4aea-ae1e-67f6f7204238"></a><a name="section-11.2.1.3"></a><p></p>
<h4><span class="Bold">Entacapone</span></h4>
<p class="First">Following administration of carbidopa, levodopa and entacapone tablets as a single dose to healthy male and female subjects, the peak concentration of entacapone in plasma was reached within 0.8 hour to 1.2 hours on average. The mean C<span class="Sub">max</span> of entacapone was about 1,200 nanogram per mL to 1,500 nanogram per mL and the AUC 1,250 nanogramâ€¢h per mL to 1,750 nanagramâ€¢h per mL after administration of different carbidopa, levodopa and entacapone tablets strengths all providing 200 mg of entacapone.</p>
<p>The plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL. Entacapone binds mainly to serum albumin.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4d4cc601-f6de-4602-bfbc-ce69e13e5e33"></a><a name="section-11.2.2"></a><p></p>
<h3><span class="Bold"><span class="Underline">Metabolism and Elimination</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_77fbdac2-d923-44d0-9a22-9557d284adcd"></a><a name="section-11.2.2.1"></a><p></p>
<h4><span class="Bold">Levodopa</span></h4>
<p class="First">The elimination half-life of levodopa, the active moiety of antiparkinsonian activity, was 1.7 hours (range 1.1 hours to 3.2 hours).</p>
<p>Levodopa is extensively metabolized to various metabolites. Two major pathways are decarboxylation by dopa decarboxylase (DDC) and O-methylation by COMT.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_47a40174-c4b2-44ac-bfd3-ce4a9c72ddeb"></a><a name="section-11.2.2.2"></a><p></p>
<h4><span class="Bold">Carbidopa</span></h4>
<p class="First">The elimination halfâ€‘life of carbidopa was on average 1.6 hours to 2 hours (range 0.7 hour to 4.0 hours).</p>
<p>Carbidopa is metabolized to two main metabolites (Î±-methyl-3-methoxy-4-hydroxyphenylpropionic acid and Î±â€‘methylâ€‘3,4-dihydroxyphenylpropionic acid). These 2 metabolites are primarily eliminated in the urine unchanged or as glucuronide conjugates. Unchanged carbidopa accounts for 30% of the total urinary excretion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8b5266e4-46a1-4a4b-9574-3cde8ee6201f"></a><a name="section-11.2.2.3"></a><p></p>
<h4><span class="Bold">Entacapone</span></h4>
<p class="First">The elimination halfâ€‘life of entacapone was on average 0.8 hour to 1 hour (0.3 hour to 4.5 hours).</p>
<p>Entacapone is almost completely metabolized prior to excretion with only a very small amount (0.2% of dose) found unchanged in urine. The main metabolic pathway is isomerization to the <span class="Italics">cis</span>-isomer, the only active metabolite. Entacapone and the <span class="Italics">cis</span>-isomer are eliminated in the urine as glucuronide conjugates. The glucuronides account for 95% of all urinary metabolites (70% as parent and 25% as <span class="Italics">cis</span>-isomer glucuronides). The glucuronide conjugate of the <span class="Italics">cis</span>-isomer is inactive. After oral administration of a <span class="Sup">14</span>C-labeled dose of entacapone, 10% of labeled parent and metabolite is excreted in urine and 90% in feces.</p>
<p>Due to short elimination halfâ€‘lives, no true accumulation of levodopa or entacapone occurs when they are administered repeatedly.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7842e560-242b-4e61-bc44-44f5fa1fba6d"></a><a name="section-11.2.3"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_58bc6f06-e4de-4be1-bd2c-78c924dec7eb"></a><a name="section-11.2.3.1"></a><p></p>
<h4><span class="Bold">Entacapone</span></h4>
<p class="First">The pharmacokinetics of entacapone have been investigated after a single 200 mg entacapone dose in subjects with normal, moderate, and severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal functions</span>, without levodopa and dopa decarboxylase inhibitor coadministration. No significant effects of renal function on the pharmacokinetics of entacapone were found. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7cbb6355-8c40-4dd8-a612-eb1ddd5af4eb"></a><a name="section-11.2.3.2"></a><p></p>
<h4><span class="Bold">Levodopa and carbidopa</span></h4>
<p class="First">No studies on the pharmacokinetics of levodopa and carbidopa in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a537895a-890d-4f9a-b717-4cbc3da799b1"></a><a name="section-11.2.4"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a21f4cdb-dd10-49bf-863e-def55f391d3a"></a><a name="section-11.2.4.1"></a><p></p>
<h4><span class="Bold">Entacapone</span></h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span> had a significant effect on the pharmacokinetics of entacapone when 200 mg entacapone was administered alone. A single 200 mg dose of entacapone, without levodopa and dopa decarboxylase inhibitor coadministration, showed approximately 2â€‘fold higher AUC and C<span class="Sub">max</span> values in patients with a history of <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span> and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (n=10) compared to normal subjects (n=10). All patients had biopsyâ€‘proven <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">liver cirrhosis</span> caused by alcohol. According to Childâ€‘Pugh grading 7 patients with liver disease had mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and 3 patients had moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. As only about 10% of the entacapone dose is excreted in urine, as parent compound and conjugated glucuronide, biliary excretion appears to be the major route of excretion of this drug. Carbidopa, levodopa and entacapone tablets should be administered with care to patients with biliary obstruction or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2f29133b-3299-4713-9e30-a44fd51d96db"></a><a name="section-11.2.4.2"></a><p></p>
<h4><span class="Bold">Levodopa and carbidopa</span></h4>
<p class="First">There are no studies on the pharmacokinetics of levodopa and carbidopa in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_3b875431-bad4-4021-b934-f28dc65ea119"></a><a name="section-11.2.5"></a><p></p>
<h3><span class="Bold">Geriatric Use</span></h3>
<p class="First">In the pharmacokinetics studies conducted in healthy volunteers following a single dose of carbidopa-, levodopa- and entacapone (as carbidopa, levodopa and entacapone tablets or as separate carbidopa/levodopa and entacapone tablets):</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_55b750d8-7946-4302-8115-04839ca5371f"></a><a name="section-11.2.5.1"></a><p></p>
<h4><span class="Bold">Levodopa</span></h4>
<p class="First">The AUC of levodopa is significantly (on average 10% to 20%) higher in elderly (60 years to 75 years) than younger subjects (45 years to 60 years). There is no significant difference in the C<span class="Sub">max</span> of levodopa between younger (45 years to 60Â years) and elderly subjects (60 years to 75 years).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_29ff2c2a-1704-4bf8-9eee-b83ceeebe52e"></a><a name="section-11.2.5.2"></a><p></p>
<h4><span class="Bold">Carbidopa</span></h4>
<p class="First">There is no significant difference in the C<span class="Sub">max</span> and AUC of carbidopa, between younger (45 years to 60 years) and elderly subjects (60 years to 75 years).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c2fba2f2-216a-4ab2-a28b-f940d0fa4b26"></a><a name="section-11.2.5.3"></a><p></p>
<h4><span class="Bold">Entacapone</span></h4>
<p class="First">The AUC of entacapone is significantly (on average, 15%) higher in elderly (60 years to 75 years) than younger subjects (45 years to 60 years). There is no significant difference in the C<span class="Sub">max</span> of entacapone between younger (45 years to 60 years) and elderly subjects (60 years to 75 years).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_46fb2043-0442-4dac-9b93-0e7d55f49c7c"></a><a name="section-11.2.6"></a><p></p>
<h3><span class="Bold">Gender</span></h3>
<p class="First">Pharmacokinetics following a single dose of carbidopa, levodopa and entacapone together, either as carbidopa, levodopa and entacapone tablets or as separate carbidopa/levodopa and entacapone tablets in healthy volunteers (age range 45 years to 74 years):</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5d5b4b1b-98e4-494e-b78b-76411f46b140"></a><a name="section-11.2.6.1"></a><p></p>
<h4><span class="Bold">Levodopa</span></h4>
<p class="First">The plasma exposure (AUC and C<span class="Sub">max</span>) of levodopa is significantly higher in females than males (on average, 40% for AUC and 30% for C<span class="Sub">max</span>). These differences are primarily explained by body weight. Other published literature showed significant gender effect (higher concentrations in females) even after correction for body weight.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_04c99a2b-aca4-4d43-81d2-e5ba80e600fa"></a><a name="section-11.2.6.2"></a><p></p>
<h4><span class="Bold">Carbidopa</span></h4>
<p class="First">There is no gender difference in the pharmacokinetics of carbidopa.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3632d696-42ec-4096-859b-e1ee7624dce3"></a><a name="section-11.2.6.3"></a><p></p>
<h4><span class="Bold">Entacapone </span></h4>
<p class="First">There is no gender difference in the pharmacokinetics of entacapone.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_caaa1b30-203c-47e6-9886-0767bd2acd04"></a><a name="section-11.2.7"></a><p></p>
<h3><span class="Bold">Drug Metabolized by COMT</span></h3>
<p class="First">When a single 400 mg dose of entacapone was given together with intravenous isoprenaline (isoproterenol) and epinephrine without coadministered levodopa and dopa decarboxylase inhibitor, the overall mean maximal changes in heart rate during infusion were about 50% and 80% higher than with placebo, for isoprenaline and epinephrine, respectively.</p>
<p>Drugs known to be metabolized by COMT should be administered with caution in patients receiving entacapone regardless of the route of administration [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_ef519b57-0bf9-4302-a74c-668e6f4a94cb">Drug Interactions (7.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_36ba68ef-be4a-45fc-aa1d-4246a5057375"></a><a name="section-11.2.8"></a><p></p>
<h3><span class="Bold">Drugs Metabolized via CYP2C9</span></h3>
<p class="First">Due to its affinity to CYP2C9 <span class="Italics">in vitro</span>, entacapone may potentially interfere with medicinal products with metabolism dependent on this isoenzyme. In an interaction study in healthy volunteers, entacapone increased the AUC of R-warfarin on average by 18%, and the INR values increased on average by 13% [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_3c6fa16d-619b-4a8b-8f80-96bfa9f7d5dc">Drug Interactions (7.11)</a></span>]<span class="Italics">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_142f8591-b161-4fa1-9f15-22afd52ca9ed"></a><a name="section-11.3"></a><p></p>
<h2>12.6 Hormone Levels</h2>
<p class="First">Of the ingredients in carbidopa, levodopa and entacapone tablets, levodopa is known to depress prolactin secretion and increase growth hormone levels.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_e82eb9f0-9d95-4dd2-9a15-39548868cdae"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_e6ba362a-3fa6-4441-a14a-84676fbf4cda"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5c7fbb04-b26e-433b-981c-834ad4051e27"></a><a name="section-12.1.1"></a><p></p>
<h3><span class="Bold">Carcinogenesis</span></h3>
<p class="First">In rats, oral administration of carbidopa-levodopa for 2 years resulted in no evidence of carcinogenicity at doses of approximately 2 times (carbidopa)-4 times (levodopa) the maximum recommended human dose (MRHD).</p>
<p>Twoâ€‘year carcinogenicity studies of entacapone were conducted in mice and rats. Mice were treated once daily by oral gavage with doses of 20, 100, or 600 mg/kg/day (0.05, 0.3, or 2 times the MRHD on a mg/m<span class="Sup">2</span> basis). Because of a high incidence of premature mortality in mice receiving the highest dose of entacapone, the mouse study is not an adequate assessment of carcinogenicity. Rats were treated with entacapone at oral doses of 20, 90, or 400 mg/kg/day. An increased incidence of renal tubular <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas was found in male rats treated with the highest dose of entacapone. Plasma exposures (AUC) associated with the highest dose not associated with increased renal tumors were approximately 5 times that in humans at the MRHD of entacapone. </p>
<p>The carcinogenic potential of entacapone administered in combination with carbidopa-levodopa has not been evaluated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_54fc8bce-b3b3-4c5a-9a96-55058623bdd3"></a><a name="section-12.1.2"></a><p></p>
<h3><span class="Bold">Mutagenesis</span></h3>
<p class="First">Carbidopa was mutagenic in the <span class="Italics">in vitro</span> bacterial reverse mutation (Ames) assay in the presence and absence of metabolic activation, and in the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> thymidine kinase (<span class="Italics">tk)</span> assay in the absence of metabolic activation. Carbidopa was negative in the <span class="Italics">in vivo</span> mouse micronucleus assay.</p>
<p>Entacapone was mutagenic and clastogenic in the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> <span class="Italics">tk</span> assay in the presence and absence of metabolic activation, and was clastogenic in cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> in the presence of metabolic activation. Entacapone, either alone or in combination with carbidopa-levodopa, was negative in the <span class="Italics">in vivo</span> mouse micronucleus and in the Ames assays.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_73cdead6-640d-4ca2-8c80-fdbe7d7cf287"></a><a name="section-12.1.3"></a><p></p>
<h3><span class="Bold">Impairment of Fertility</span></h3>
<p class="First">In reproduction studies, no effects on fertility were found in rats receiving carbidopa-levodopa at doses of approximately 2 times (carbidopa)-4 times (levodopa) the MRHD.</p>
<p>In rats treated orally with entacapone (up to 700 mg/kg/day), no effects on fertility or general reproductive performance were observed. Plasma exposures (AUC) at the highest dose tested were approximately 30 times that in humans at the MRHD of entacapone. Delayed mating was evident in females at the highest dose tested.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_81cfd7c4-bc6d-4553-939c-ca3851565fb2"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The effectiveness of entacapone as an adjunct to levodopa in the treatment of Parkinsonâ€™s disease was established in three 24-week multicenter, randomized, doubleâ€‘blind, placeboâ€‘controlled studies in patients with Parkinsonâ€™s disease. In 2 of these studies (Studies 1 and 2), the patientsâ€™ disease was â€œfluctuatingâ€?, i.e., was characterized by documented periods of â€œOnâ€? (periods of relatively good functioning) and â€œOffâ€? (periods of relatively poor functioning), despite optimum levodopa therapy. There was also a withdrawal period following 6 months of treatment. In the third trial patients were not required to have been experiencing fluctuations. Prior to the controlled part of these studies, patients were stabilized on levodopa for 2 weeks to 4 weeks.</p>
<p>There is limited experience using entacapone in patients who do not experience fluctuations.</p>
<p>In Studies 1 and 2, patients were randomized to receive placebo or entacapone 200 mg administered concomitantly with each dose of carbidopa/levodopa (up to 10 times daily, but patients averaged 4 doses to 6 doses per day). The doubleâ€‘blind portion of both studies was 6 months long. Patients periodically recorded the time spent in the â€œOnâ€? and â€œOffâ€? states in home diaries throughout the duration of the trial. In one study, conducted in the Nordic countries, the primary outcome measure was the total mean time spent in the â€œOnâ€? state during an 18 hour diary recorded day (6 a.m. to midnight). In the other study, the primary outcome measure was the proportion of awake time spent over 24 hours in the â€œOnâ€? state.</p>
<p>In addition to the primary outcome measure, the amount of time spent in the â€œOffâ€? state was evaluated, and patients were also evaluated by subparts of the Unified Parkinsonâ€™s Disease Rating Scale (UPDRS), a frequently used multiâ€‘item rating scale intended to assess mentation (Part I), activities of daily living (Part II), motor function (Part III), complications of therapy (Part IV), and disease staging (Part V and VI); an investigatorâ€™s and patientâ€™s global assessment of clinical condition, a 7â€‘point subjective scale designed to assess global functioning in Parkinsonâ€™s disease; and the change in daily carbidopa/levodopa dose.</p>
<p>In Study 1, 171 patients were randomized in 16 centers in Finland, Norway, Sweden, and Denmark (Study 1), all of whom received concomitant levodopa plus dopa decarboxylase inhibitor (either carbidopa/levodopa or benserazide/levodopa). In Study 2, 205 patients were randomized in 17 centers in North America (US and Canada); all patients received concomitant carbidopa/levodopa.</p>
<p>The following tables (Table 4 and Table 5) display the results of these two studies:</p>
<a name="_RefID0E4QAI"></a><table width="100%">
<caption><span>Table 4: Efficacy Results of Study 1</span></caption>
<col width="37%">
<col width="21%">
<col width="21%">
<col width="21%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Mean; the month 6 values represent the average of weeks 8, 16, and 24, by protocolâ€‘defined outcome measure.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>P values for Secondary Measures are nominal P values without any adjustment for multiplicity.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd>Not an endpoint for this study but primary endpoint in the North American Study.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">Â§</a></dt>
<dd>At least one category change at endpoint.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">Â¶</a></dt>
<dd>Not significant.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Primary Measure from Home Diary (from an 18</span>â€‘<span class="Bold">hour Diary Day)</span></p></td></tr>
<tr>
<td></td>
<td></td>
<td align="center"><p class="First">Change from</p></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td align="center"><p class="First">Baseline at</p></td>
<td align="center"><p class="First">pâ€‘value</p></td>
</tr>
<tr>
<td></td>
<td class="Botrule" align="center"><p class="First">Baseline</p></td>
<td class="Botrule" align="center"><p class="First">Month 6<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule" align="center"><p class="First">vs. placebo</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Hours of Awake Time â€œOnâ€?</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">9.2</p></td>
<td align="center"><p class="First">+0.1</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">9.3</p></td>
<td align="center"><p class="First">+1.5</p></td>
<td align="center"><p class="First">less than 0.001</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Duration of â€œOnâ€? Time After First AM Dose (Hrs)</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">2.2</p></td>
<td align="center"><p class="First">0.0</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Entacapone</p></td>
<td class="Botrule" align="center"><p class="First">2.1</p></td>
<td class="Botrule" align="center"><p class="First">+0.2</p></td>
<td class="Botrule" align="center"><p class="First">less than 0.05</p></td>
</tr>
<tr><td class="Botrule" align="center" colspan="4"><p class="First"><span class="Bold">Secondary Measures from Home Diary (from an 18</span>â€‘<span class="Bold">hour Diary Day)</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a></p></td></tr>
<tr>
<td><p class="First"><span class="Bold">Hours of Awake Time â€œOffâ€?</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">5.3</p></td>
<td align="center"><p class="First">0.0</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">5.5</p></td>
<td align="center"><p class="First">â€‘1.3</p></td>
<td align="center"><p class="First">less than 0.001</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Proportion of Awake Time â€œOnâ€?</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a><span class="Bold"> (%)</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">63.8</p></td>
<td align="center"><p class="First">+0.6</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">62.7</p></td>
<td align="center"><p class="First">+9.3</p></td>
<td align="center"><p class="First">less than 0.001</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Levodopa Total Daily Dose (mg)</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">705</p></td>
<td align="center"><p class="First">+14</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">701</p></td>
<td align="center"><p class="First">â€‘87</p></td>
<td align="center"><p class="First">less than 0.001</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Frequency of Levodopa Daily Intakes</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">6.1</p></td>
<td align="center"><p class="First">+0.1</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Entacapone</p></td>
<td class="Botrule" align="center"><p class="First">6.2</p></td>
<td class="Botrule" align="center"><p class="First">â€‘ 0.4</p></td>
<td class="Botrule" align="center"><p class="First">less than 0.001</p></td>
</tr>
<tr><td class="Botrule" align="center" colspan="4"><p class="First"><span class="Bold">Other Secondary Measures</span><a href="#footnote-2" class="Sup">â€ </a></p></td></tr>
<tr>
<td></td>
<td></td>
<td align="center"><p class="First">Change from</p></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td align="center"><p class="First">Baseline at</p></td>
<td align="center"><p class="First">pâ€‘value</p></td>
</tr>
<tr>
<td></td>
<td class="Botrule" align="center"><p class="First">Baseline</p></td>
<td class="Botrule" align="center"><p class="First">Month 6</p></td>
<td class="Botrule" align="center"><p class="First">vs. placebo</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Investigatorâ€™s Global (overall) % Improved</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">Â§</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">â€“</p></td>
<td align="center"><p class="First">28</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">â€“</p></td>
<td align="center"><p class="First">56</p></td>
<td align="center"><p class="First">less than 0.01</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Patientâ€™s Global (overall) % Improved</span><a href="#footnote-4" class="Sup">Â§</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">â€“</p></td>
<td align="center"><p class="First">22</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">â€“</p></td>
<td align="center"><p class="First">39</p></td>
<td align="center"><p class="First">N.S.<a name="footnote-reference-5" href="#footnote-5" class="Sup">Â¶</a></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">UPDRS Total</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">37.4</p></td>
<td align="center"><p class="First">â€‘1.1</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">38.5</p></td>
<td align="center"><p class="First">â€‘4.8</p></td>
<td align="center"><p class="First">less than 0.01</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">UPDRS Motor</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">24.6</p></td>
<td align="center"><p class="First">â€‘0.7</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">25.5</p></td>
<td align="center"><p class="First">â€‘3.3</p></td>
<td align="center"><p class="First">less than 0.05</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">UPDRS ADL</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">11.0</p></td>
<td align="center"><p class="First">â€‘0.4</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Entacapone</p></td>
<td class="Botrule" align="center"><p class="First">11.2</p></td>
<td class="Botrule" align="center"><p class="First">â€‘1.8</p></td>
<td class="Botrule" align="center"><p class="First">less than 0.05</p></td>
</tr>
</tbody>
</table>
<a name="_RefID0EOBBI"></a><table width="100%">
<caption><span>Table 5: Efficacy Results of Study 2</span></caption>
<col width="56%">
<col width="15%">
<col width="15%">
<col width="15%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Mean; the month 6 values represent the average of weeks 8, 16, and 24, by protocolâ€‘defined outcome measure.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">â€ </a></dt>
<dd>P values for Secondary Measures are nominal P values without any adjustment for multiplicity.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">â€¡</a></dt>
<dd>Not significant.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">Â§</a></dt>
<dd>At least one category change at endpoint.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">Â¶</a></dt>
<dd>Score change at endpoint similarly to the Nordic Study.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="4"><p class="First"><span class="Bold">Primary Measure from Home Diary (for a 24</span>â€‘<span class="Bold">hour Diary Day)</span></p></td></tr>
<tr>
<td></td>
<td></td>
<td align="center"><p class="First">Change from</p></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td align="center"><p class="First">Baseline at</p></td>
<td align="center"><p class="First">pâ€‘value</p></td>
</tr>
<tr>
<td></td>
<td class="Botrule" align="center"><p class="First">Baseline</p></td>
<td class="Botrule" align="center"><p class="First">Month 6<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></p></td>
<td class="Botrule" align="center"><p class="First">vs. placebo</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Percent of Awake Time â€œOnâ€?</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">60.8</p></td>
<td align="center"><p class="First">+2.0</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Entacapone</p></td>
<td class="Botrule" align="center"><p class="First">60.0</p></td>
<td class="Botrule" align="center"><p class="First">+6.7</p></td>
<td class="Botrule" align="center"><p class="First">less than 0.05</p></td>
</tr>
<tr><td class="Botrule" align="center" colspan="4"><p class="First"><span class="Bold">Secondary Measures from Home Diary (for a 24</span>â€‘<span class="Bold">hour Diary Day)</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">â€ </a></p></td></tr>
<tr>
<td><p class="First"><span class="Bold">Hours of Awake Time â€œOffâ€?</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">6.6</p></td>
<td align="center"><p class="First">â€‘0.3</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">6.8</p></td>
<td align="center"><p class="First">â€‘1.2</p></td>
<td align="center"><p class="First">less than 0.01</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Hours of Awake Time â€œOnâ€?</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">10.3</p></td>
<td align="center"><p class="First">+0.4</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">10.2</p></td>
<td align="center"><p class="First">+1.0</p></td>
<td align="center"><p class="First">N.S.â€¡</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Levodopa Total Daily Dose (mg)</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">758</p></td>
<td align="center"><p class="First">+19</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">804</p></td>
<td align="center"><p class="First">â€‘93</p></td>
<td align="center"><p class="First">less than 0.001</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Frequency of Levodopa Daily Intakes</span></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">6.0</p></td>
<td align="center"><p class="First">+0.2</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Entacapone</p></td>
<td class="Botrule" align="center"><p class="First">6.2</p></td>
<td class="Botrule" align="center"><p class="First">0.0</p></td>
<td class="Botrule" align="center"><p class="First">N.S.<a name="footnote-reference-8" href="#footnote-8" class="Sup">â€¡</a></p></td>
</tr>
<tr><td class="Botrule" align="center" colspan="4"><p class="First"><span class="Bold">Other Secondary Measures</span><a href="#footnote-7" class="Sup">â€ </a></p></td></tr>
<tr>
<td></td>
<td></td>
<td align="center"><p class="First">Change from</p></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td align="center"><p class="First">Baseline at</p></td>
<td align="center"><p class="First">pâ€‘value</p></td>
</tr>
<tr>
<td></td>
<td class="Botrule" align="center"><p class="First">Baseline</p></td>
<td class="Botrule" align="center"><p class="First">Month 6</p></td>
<td class="Botrule" align="center"><p class="First">vs. placebo</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Investigatorâ€™s Global (overall) % Improved</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">Â§</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">â€“</p></td>
<td align="center"><p class="First">21</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">â€“</p></td>
<td align="center"><p class="First">34</p></td>
<td align="center"><p class="First">less than 0.05</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Patientâ€™s Global (overall) % Improved</span><a href="#footnote-9" class="Sup">Â§</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">â€“</p></td>
<td align="center"><p class="First">20</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">â€“</p></td>
<td align="center"><p class="First">31</p></td>
<td align="center"><p class="First">less than 0.05</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">UPDRS Total</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">Â¶</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">35.6</p></td>
<td align="center"><p class="First">+2.8</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">35.1</p></td>
<td align="center"><p class="First">â€‘0.6</p></td>
<td align="center"><p class="First">less than 0.05</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">UPDRS Motor</span><a href="#footnote-10" class="Sup">Â¶</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">22.6</p></td>
<td align="center"><p class="First">+1.2</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">22.0</p></td>
<td align="center"><p class="First">â€‘0.9</p></td>
<td align="center"><p class="First">less than 0.05</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">UPDRS ADL</span><a href="#footnote-10" class="Sup">Â¶</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">11.7</p></td>
<td align="center"><p class="First">+1.1</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Entacapone</p></td>
<td class="Botrule" align="center"><p class="First">11.9</p></td>
<td class="Botrule" align="center"><p class="First">0.0</p></td>
<td class="Botrule" align="center"><p class="First">less than 0.05</p></td>
</tr>
</tbody>
</table>
<p>Effects on â€œOnâ€? time did not differ by age, sex, weight, disease severity at baseline, levodopa dose and concurrent treatment with dopamine agonists or selegiline.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0facc08e-df26-4b00-a956-78af4d087b8a"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Italics">Withdrawal of entacapone:</span> In Study 2, abrupt withdrawal of entacapone, without alteration of the dose of carbidopa/levodopa, resulted in a significant worsening of fluctuations, compared to placebo. In some cases, symptoms were slightly worse than at baseline, but returned to approximately baseline severity within 2 weeks following levodopa dose increase on average by 80 mg. In Study 1, similarly, a significant worsening of parkinsonian symptoms was observed after entacapone withdrawal, as assessed 2 weeks after drug withdrawal. At this phase, the symptoms were approximately at baseline severity following levodopa dose increase by about 50 mg.</p>
<p>In the third placeboâ€‘controlled trial (Study 3), a total of 301 patients were randomized in 32 centers in Germany and Austria. In this trial, as in the other 2 studies, entacapone 200 mg was administered with each dose of levodopa and dopa decarboxylase inhibitor (up to 10 times daily) and UPDRS Parts II and III and total daily â€œOnâ€? time were the primary measures of effectiveness. Results for the primary measures, as well as for some secondary measures are presented in Table 6. </p>
<a name="_RefID0EORBI"></a><table width="100%">
<caption><span>Table 6: Efficacy Results of Study 3</span></caption>
<col width="55%">
<col width="15%">
<col width="15%">
<col width="15%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Total population; score change at endpoint.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">â€ </a></dt>
<dd>Fluctuating population, with 5 doses to 10 doses; score change at endpoint.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">â€¡</a></dt>
<dd>Not significant.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">Â§</a></dt>
<dd>P values for Secondary Measures are nominal P values without any adjustment for multiplicity.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">Â¶</a></dt>
<dd>Total population; at least one category change at endpoint.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" colspan="4"><p class="First"><span class="Bold">Primary Measures</span></p></td></tr>
<tr>
<td></td>
<td></td>
<td align="center"><p class="First">Change from</p></td>
<td align="center"><p class="First">pâ€‘value</p></td>
</tr>
<tr>
<td></td>
<td></td>
<td align="center"><p class="First">Baseline at</p></td>
<td align="center"><p class="First">vs. placebo</p></td>
</tr>
<tr>
<td></td>
<td class="Botrule" align="center"><p class="First">Baseline</p></td>
<td class="Botrule" align="center"><p class="First">Month 6</p></td>
<td class="Botrule" align="center"><p class="First">(LOCF)</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">UPDRS ADL</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">12.0</p></td>
<td align="center"><p class="First">+0.5</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">12.4</p></td>
<td align="center"><p class="First">â€‘0.4</p></td>
<td align="center"><p class="First">less than 0.05</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">UPDRS Motor</span><a href="#footnote-11" class="Sup">*</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">24.1</p></td>
<td align="center"><p class="First">+0.1</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">24.9</p></td>
<td align="center"><p class="First">â€‘2.5</p></td>
<td align="center"><p class="First">less than 0.05</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Hours of Awake Time â€œOnâ€? (Home Diary)</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">â€ </a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">10.1</p></td>
<td align="center"><p class="First">+0.5</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Entacapone</p></td>
<td class="Botrule" align="center"><p class="First">10.2</p></td>
<td class="Botrule" align="center"><p class="First">+1.1</p></td>
<td class="Botrule" align="center"><p class="First">N.S.<a name="footnote-reference-13" href="#footnote-13" class="Sup">â€¡</a></p></td>
</tr>
<tr><td class="Botrule" colspan="4"><p class="First"><span class="Bold">Secondary Measures</span><a name="footnote-reference-14" href="#footnote-14" class="Sup">Â§</a></p></td></tr>
<tr>
<td></td>
<td></td>
<td align="center"><p class="First">Change from</p></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td align="center"><p class="First">Baseline at</p></td>
<td align="center"><p class="First">pâ€‘value</p></td>
</tr>
<tr>
<td></td>
<td class="Botrule" align="center"><p class="First">Baseline</p></td>
<td class="Botrule" align="center"><p class="First">Month 6</p></td>
<td class="Botrule" align="center"><p class="First">vs. placebo</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">UPDRS Total</span><a href="#footnote-11" class="Sup">*</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">37.7</p></td>
<td align="center"><p class="First">+0.6</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">39.0</p></td>
<td align="center"><p class="First">â€‘3.4</p></td>
<td align="center"><p class="First">less than 0.05</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Percent of Awake Time â€œOnâ€? (Home Diary)</span><a href="#footnote-12" class="Sup">â€ </a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">59.8</p></td>
<td align="center"><p class="First">+3.5</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">62.0</p></td>
<td align="center"><p class="First">+6.5</p></td>
<td align="center"><p class="First">N.S.<a href="#footnote-13" class="Sup">â€¡</a></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Hours of Awake Time â€œOffâ€? (Home Diary)</span><a href="#footnote-12" class="Sup">â€ </a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">6.8</p></td>
<td align="center"><p class="First">â€‘0.6</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">6.3</p></td>
<td align="center"><p class="First">â€‘1.2</p></td>
<td align="center"><p class="First">0.07</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Levodopa Total Daily Dose (mg)</span><a href="#footnote-11" class="Sup">*</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">572</p></td>
<td align="center"><p class="First">+4</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone </p></td>
<td align="center"><p class="First">566</p></td>
<td align="center"><p class="First">â€‘35</p></td>
<td align="center"><p class="First">N.S.<a href="#footnote-13" class="Sup">â€¡</a></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Frequency of Levodopa Daily Intake</span><a href="#footnote-11" class="Sup">*</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">5.6</p></td>
<td align="center"><p class="First">+0.2</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr>
<td><p class="First">Entacapone</p></td>
<td align="center"><p class="First">5.4</p></td>
<td align="center"><p class="First">0.0</p></td>
<td align="center"><p class="First">less than 0.01</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Global (overall) % Improved</span><a name="footnote-reference-15" href="#footnote-15" class="Sup">Â¶</a></p></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Placebo</p></td>
<td align="center"><p class="First">â€“</p></td>
<td align="center"><p class="First">34</p></td>
<td align="center"><p class="First">â€“</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Entacapone</p></td>
<td class="Botrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule" align="center"><p class="First">38</p></td>
<td class="Botrule" align="center"><p class="First">N.S.<a href="#footnote-13" class="Sup">â€¡</a></p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_94081a3b-d6e6-4654-a418-75d422a4893c"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Carbidopa, Levodopa and Entacapone Tablets are supplied as filmâ€‘coated tablets for oral administration in the following six strengths:</p>
<p>Carbidopa, levodopa and entacapone filmâ€‘coated tablets containing 12.5 mg of carbidopa, 50 mg of levodopa and 200 mg of entacapone. </p>
<p>The round, biâ€‘convex shaped tablets are brownish- or greyish-red, unscored, and embossed â€œSTOâ€? over â€œ50â€? on one side of the tablet and plain on the other side.</p>
<p>HDPE bottle of 100 tabletsÂ Â Â Â Â Â  NDC 0378-8300-01</p>
<p>Carbidopa, levodopa and entacapone filmâ€‘coated tablets containing 18.75 mg of carbidopa, 75 mg of levodopa and 200 mg of entacapone. </p>
<p>The oval-shaped tablets are light brownish red, unscored and embossed with â€œSTOâ€? over â€œ75â€? on one side of the tablet and plain on the other side. </p>
<p>HDPE bottle of 100 tabletsÂ Â Â Â Â Â  NDC 0378-8301-01</p>
<p>Carbidopa, levodopa and entacapone filmâ€‘coated tablets containing 25 mg of carbidopa, 100 mg of levodopa and 200 mg of entacapone. </p>
<p>The ovalâ€‘shaped tablets are brownish- or greyish-red, unscored, and embossed â€œSTOâ€? over â€œ100â€? on one side of the tablet and plain on the other side.</p>
<p>HDPE bottle of 100 tabletsÂ Â Â Â Â Â  NDC 0378â€‘8302â€‘01</p>
<p>Carbidopa, levodopa and entacapone filmâ€‘coated tablets containing 31.25 mg of carbidopa, 125 mg of levodopa and 200 mg of entacapone. </p>
<p>The oval-shaped tablets are light brownish red, unscored and embossed with â€œSTOâ€? over â€œ125â€? on one side of the tablet and plain on the other side.</p>
<p>HDPE bottle of 100 tabletsÂ Â Â Â Â Â  NDC 0378-8303-01</p>
<p>Carbidopa, levodopa and entacapone filmâ€‘coated tablets containing 37.5 mg of carbidopa, 150 mg of levodopa and 200 mg of entacapone</p>
<p>The elongated-ellipse shaped tablets are brownish- or greyish-red, unscored, and embossed â€œSTOâ€? over â€œ150â€? on one side of the tablet and plain on the other side. </p>
<p>HDPE bottle of 100 tabletsÂ Â Â Â Â Â  NDC 0378â€‘8304â€‘01</p>
<p>Carbidopa, levodopa and entacapone filmâ€‘coated tablets containing 50 mg of carbidopa, 200 mg of levodopa and 200 mg of entacapone</p>
<p>The oval shaped tablets are dark brownish red, unscored, and embossed â€œSTOâ€? over â€œ200â€? on one side of the tablet and plain on the other side. </p>
<p>HDPE bottle of 100 tabletsÂ Â Â Â Â Â  NDC 0378-8305-01</p>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15Â°C to 30Â°C (59Â°F to 86Â°F). </p>
<p>[See USP Controlled Room Temperature.]</p>
<p>Dispense in tight container (USP).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_87a2c827-6874-4f85-817a-9e6e7aed88a4"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep During Activities of Daily Living and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></span></p>
<p>Advise patients about the potential for sedating effects associated with carbidopa, levodopa and entacapone tablets including <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and the possibility of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while engaged in activities of daily living. Because <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> can be a frequent adverse reaction with potentially serious consequences, patients should not drive a motor vehicle, operate heavy machinery or engage in other potentially dangerous activities until they have gained sufficient experience with carbidopa, levodopa and entacapone tablets to determine whether or not it affects their mental and/or motor performance adversely [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_c7922561-f847-4818-be4a-c2c1b41717e6">Warnings and Precautions (5.1)</a></span>]. Advise patients that if increased <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> or episodes of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep during activities of daily living (e.g., conversations, eating, driving a motor vehicle, etc.) are experienced at any time during treatment, they should not drive or participate in potentially dangerous activities until they have contacted their physician.</p>
<p>Advise patients to speak with their health care prescriber before taking alcohol, sedating medications, or other CNS depressants (e.g., benzodiazepines, antipsychotics, antidepressants, etc.) because of the possible additive effects in combination with carbidopa, levodopa and entacapone tablets. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></span></p>
<p>Advise patients that they may develop symptomatic (or asymptomatic) postural (orthostatic) <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or non-<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> while taking carbidopa, levodopa and entacapone tablets. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur more frequently during initial therapy. Patients should not rise rapidly after sitting or lying down, especially if they have been doing so for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> and especially at the initiation of treatment with carbidopa, levodopa and entacapone tablets.</p>
<p>Advise patients about the potential for <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> in patients using dopamine agonists. For this reason, inform patients about the possibility of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> while taking carbidopa, levodopa and entacapone tablets [<span class="Italics">see <a href="#ID_e16a3ee8-1254-480c-b075-11c1a491461d">Warnings and Precautions (5.2)</a></span>].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesias</span></span></p>
<p>Inform patients that carbidopa, levodopa and entacapone tablets may cause and/or exacerbate pre-existing <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span> [see <span class="Italics"><a href="#ID_c5d32ce3-ca07-4527-a14d-645aa13a2593">Warnings and Precautions (5.3)</a></span>]. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> and/or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span>-Like Behavior</span></p>
<p>Inform patients that <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> and other <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior can occur while taking carbidopa, levodopa and entacapone tablets [<span class="Italics">see <a href="#ID_6e375e17-13db-4d21-8bc1-b48074c20e03">Warnings and Precautions (5.5)</a></span>].</p>
<p><span class="Bold">Impulse Control and/or Compulsive Behaviors</span></p>
<p>Advise patients that they may experience impulse control and/or compulsive behaviors while taking one or more of the medications used for the treatment of Parkinsonâ€™s disease, including carbidopa, levodopa and entacapone tablets. Ask patients about the development of new or increased <span class="product-label-link" type="condition" conceptid="4023166" conceptname="Gambling">gambling</span> urges, sexual urges, urges for uncontrolled spending, or other intense urges while being treated with carbidopa, levodopa and entacapone tablets. Advise patients to inform their physician or health care provider if they experience new or increased <span class="product-label-link" type="condition" conceptid="4023166" conceptname="Gambling">gambling</span> urges, increased sexual urges or other intense urges while taking carbidopa, levodopa and entacapone tablets. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking carbidopa, levodopa and entacapone tablets [<span class="Italics">see <a href="#ID_a8348c0f-3278-4ad7-9b0a-1f67234c3dea">Warnings and Precautions (5.6)</a>].</span></p>
<p><span class="Bold">Withdrawal-Emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></span></p>
<p>Advise patients that they may develop <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> as part of a syndrome resembling NMS and possibly with other clinical features (e.g., <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic dysfunction</span>, hyper- or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, etc.). This <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> syndrome may particularly occur with dose reductions or withdrawal of carbidopa, levodopa and entacapone tablets but may also develop after initiation of treatment. Advise patients to contact their healthcare provider if they wish to discontinue or decrease the dose of carbidopa, levodopa and entacapone tablets and to contact a health care provider if they develop <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> [<span class="Italics">see <a href="#ID_dd7edf28-a08d-42a7-80f7-a015568ad9dd">Warnings and Precautions (5.7)</a>].</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></span></p>
<p>Inform the patients that <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may occur with carbidopa, levodopa and entacapone tablets and it may have a delayed onset. Sometimes prolonged <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may be caused by <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the large intestine). Patients with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> should drink fluids to maintain adequate hydration and monitor for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. If <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> associated with carbidopa, levodopa and entacapone tablets is prolonged, discontinuing the drug is expected to lead to resolution. If <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> continues after stopping carbidopa, levodopa and entacapone tablets, further diagnostic investigations may be needed. In some cases, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may be associated with <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> [<span class="Italics">see <a href="#ID_0f5dfc39-db5d-41ce-b0ed-679998452936">Warnings and Precautions (5.8)</a></span>].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></span></p>
<p>Advise patients that they may develop <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> if they experience prolonged motor activity including <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>. This event may also be associated with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> [<span class="Italics">see <a href="#ID_e1a20273-e5d9-4c87-9e18-c82b15c83d96">Warnings and Precautions (5.9)</a></span>]. </p>
<p><span class="Bold">Melanoma</span></p>
<p>Advise patients with Parkinsonâ€™s disease that they have a higher risk of developing melanoma. Advise patients to have their skin examined on a regular basis by a qualified healthcare provider (e.g., dermatologist) and to monitor for melanomas frequently and on a regular basis when using carbidopa, levodopa and entacapone tablets [<span class="Italics">see <a href="#ID_4533d731-4611-412b-b767-40a54b74e9f3">Warnings and Precautions (5.10)</a></span>].</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></span></p>
<p>Inform patients that carbidopa, levodopa and entacapone tablets may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may occur more frequently during initial therapy and may require dose adjustment.</p>
<p><span class="Bold">Instructions for Use</span></p>
<p>Instruct patients to take carbidopa, levodopa and entacapone tablets only as prescribed. Instruct patients to only take a single tablet of carbidopa, levodopa and entacapone at each dosing interval. Instruct patients not to take multiple tablets or additional portions of tablets to achieve a higher dose of levodopa. Advise patients not to split, crush, or chew carbidopa, levodopa and entacapone tablets. </p>
<p>Inform the patient that carbidopa, levodopa and entacapone tablets are a formulation of carbidopa/levodopa combined with entacapone that is designed to begin release of ingredients within 30 minutes after ingestion. It is important that carbidopa, levodopa and entacapone tablets be taken at regular intervals according to the schedule outlined by the physician. Caution the patient not to change the prescribed dosage regimen and not to add any additional antiparkinsonian medications, including other carbidopa/levodopa preparations, without first consulting the physician.</p>
<p>Advise patients that â€œoffâ€? episodes (â€œwearingâ€‘offâ€? of drug effect) occur at the end of the dosing interval but unpredictable â€œoffâ€? episodes may occur at any time. Advise the patient to notify a health care provider for possible treatment adjustments if such response poses a problem to the patientâ€™s everyday life.</p>
<p>Advise patients that dark coloration (red, brown, or black) may appear in saliva, urine, or sweat after taking carbidopa, levodopa and entacapone tablets. Although the color appears to be clinically insignificant, garments may become discolored.</p>
<p>Advise patients that a change in diet to foods that are high in protein may delay the absorption of levodopa. Excessive acidity also delays stomach emptying, thus delaying the absorption of levodopa. Iron salts (such as in multiâ€‘vitamin tablets) may also reduce the effectiveness of carbidopa, levodopa and entacapone tablets. </p>
<p><span class="Bold">Pregnancy and Breastfeeding</span></p>
<p>Carbidopa and levodopa are known to affect embryo-fetal development in the rabbit and decrease the number of live pups delivered by rats. Instruct patients to notify their physicians if they become pregnant or intend to become pregnant during therapy [<span class="Italics">see</span>Â <span class="Italics"><a href="#ID_8958a2c8-77fb-4f73-a15a-1670c7258f20">Use in Specific Populations (8.1)</a></span>].</p>
<p>Carbidopa is known to be excreted into milk in rats. Because of the possibility that carbidopa and levodopa may be excreted into human milk, instruct patients to notify their physicians if they intend to breastfeed or are breastfeeding an infant [<span class="Italics">seeÂ <a href="#ID_1b1ca39d-443d-4a54-a93c-e89674196465">Use in Specific Populations (8.3)</a></span>]. </p>
<p>Distributed by:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Orion Corporation</span><br>ORION PHARMA<br>Orionintie 1, FINâ€‘02200 Espoo, Finland.</p>
<p>Revised: 07/2014<br>CLENTC:R2</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_11b19966-e67e-49ca-bbfc-cca9b316300a"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ 12.5 mg/50 mg/200 mg </h1>
<p class="First"><span class="Bold">NDC 0378-8300-01</span></p>
<p><span class="Bold">Carbidopa, Levodopa</span><br><span class="Bold">and Entacapone</span><br><span class="Bold">Tablets</span></p>
<p>Each film-coated tablet contains:<br>Carbidopa, USP . . . . . . 12.5 mg<br>Levodopa, USP . . . . . . . 50 mg<br>and<br>Entacapone . . . . . . . . . 200 mg</p>
<p><span class="Bold">Do not combine tablets to achieve a higher</span><br><span class="Bold">strength tablet due to the risk of entacapone</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
<p><span class="Bold">Rx onlyÂ Â Â Â Â 100 Tablets</span></p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">Store at 25Â°C (77Â°F);</span><br><span class="Bold">excursions permitted to</span><br><span class="Bold">15Â°C to 30Â°C (59Â°F to 86Â°F).</span></p>
<p><span class="Bold">Dosage:</span>Â See package insert.</p>
<p>Swallow whole. Do not crush,<br>split, or chew.</p>
<p>Store at 25Â°C (77Â°F);<br>excursions permitted to<br>15Â°C to 30Â°C (59Â°F to 86Â°F).</p>
<p>[See USP Controlled Room<br>Temperature.]</p>
<p>Dispense in a tight container, (USP).</p>
<p>Keep this and all drugs out of<br>the reach of children.</p>
<p>Manufactured by:<br>Orion Corporation<br>ORION PHARMA<br>Orionintie 1,<br>FIN-02200 Espoo, Finland.</p>
<p>Distributed by:<br>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">RM8300A1</span></p>
<div class="Figure">
<a name="id-680577368"></a><img alt="Carbidopa, Levodopa and Entacapone Tablets 12.5 mg, 50 mg and 200 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4a535af2-16fc-4fdf-92ec-7941ef23a63a&amp;name=image-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_93571468-1182-4de8-bac5-67e08960a53a"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ 18.75 mg/75 mg/200 mg </h1>
<p class="First"><span class="Bold">NDC 0378-8301-01</span></p>
<p><span class="Bold">Carbidopa, Levodopa </span><br><span class="Bold">and Entacapone </span><br><span class="Bold">Tablets</span></p>
<p>Each film-coated tablet contains:<br>Carbidopa, USP . . . . . . 18.75 mg<br>Levodopa, USP . . . . . . . 75 mg<br>and<br>Entacapone . . . . . . . . . 200 mg</p>
<p><span class="Bold">Do not combine tablets to achieve a higher</span><br><span class="Bold">strength tablet due to the risk of entacapone</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
<p><span class="Bold">Rx onlyÂ Â Â Â Â 100 Tablets</span></p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">Dosage:</span>Â See package insert.</p>
<p>Swallow whole. Do not crush,<br>split, or chew.</p>
<p>Store at 25Â°C (77Â°F);<br>excursions permitted to<br>15Â°C to 30Â°C (59Â°F to 86Â°F).</p>
<p>[See USP Controlled Room<br>Temperature.]</p>
<p>Dispense in a tight container, (USP).</p>
<p>Keep this and all drugs out of<br>the reach of children.</p>
<p>Manufactured by:<br>Orion Corporation<br>ORION PHARMA<br>Orionintie 1,<br>FIN-02200 Espoo, Finland.</p>
<p>Distributed by:<br>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">RM8301A1</span></p>
<div class="Figure">
<a name="id1086352078"></a><img alt="Carbidopa, Levodopa and Entacapone Tablets 18.75 mg, 75 mg and 200 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4a535af2-16fc-4fdf-92ec-7941ef23a63a&amp;name=image-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_8b839b66-afe9-4c58-a894-e9c62ce98418"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ 25 mg/100 mg/200 mg </h1>
<p class="First"><span class="Bold">NDC 0378-8302-01</span></p>
<p><span class="Bold">Carbidopa, Levodopa</span><br><span class="Bold">and Entacapone</span><br><span class="Bold">Tablets</span></p>
<p>Each film-coated tablet contains:<br>Carbidopa, USP . . . . . . 25 mg<br>Levodopa, USP . . . . . . . 100 mg<br>and<br>Entacapone . . . . . . . . . 200 mg</p>
<p><span class="Bold">Do not combine tablets to achieve a higher</span><br><span class="Bold">strength tablet due to the risk of entacapone</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
<p><span class="Bold">Rx onlyÂ Â Â Â Â 100 Tablets</span></p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">Dosage:</span>Â See package insert.</p>
<p>Swallow whole. Do not crush,<br>split, or chew.</p>
<p>Store at 25Â°C (77Â°F);<br>excursions permitted to<br>15Â°C to 30Â°C (59Â°F to 86Â°F).</p>
<p>[See USP Controlled Room<br>Temperature.]</p>
<p>Dispense in a tight container, (USP).</p>
<p>Keep this and all drugs out of<br>the reach of children.</p>
<p>Manufactured by:<br>Orion Corporation<br>ORION PHARMA<br>Orionintie 1,<br>FIN-02200 Espoo, Finland.</p>
<p>Distributed by:<br>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">RM8302A1</span></p>
<div class="Figure">
<a name="id1007939987"></a><img alt="Carbidopa, Levodopa and Entacapone Tablets 25 mg, 100 mg and 200 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4a535af2-16fc-4fdf-92ec-7941ef23a63a&amp;name=image-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_8d1477f9-98d9-41ff-8605-e9d1b51c7141"></a><a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ 31.25 mg/125 mg/200 mg </h1>
<p class="First"><span class="Bold">NDC 0378-8303-01</span></p>
<p><span class="Bold">Carbidopa, Levodopa</span><br><span class="Bold">and Entacapone</span><br><span class="Bold">Tablets</span></p>
<p>Each film-coated tablet contains:<br>Carbidopa, USP . . . . . . 31.25 mg<br>Levodopa, USP . . . . . . . 125 mg<br>and<br>Entacapone . . . . . . . . . 200 mg</p>
<p><span class="Bold">Do not combine tablets to achieve a higher</span><br><span class="Bold">strength tablet due to the risk of entacapone</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
<p><span class="Bold">Rx onlyÂ Â Â Â Â 100 Tablets</span></p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">Dosage:</span>Â See package insert.</p>
<p>Swallow whole. Do not crush,<br>split, or chew.</p>
<p>Store at 25Â°C (77Â°F);<br>excursions permitted to<br>15Â°C to 30Â°C (59Â°F to 86Â°F).</p>
<p>[See USP Controlled Room<br>Temperature.]</p>
<p>Dispense in a tight container, (USP).</p>
<p>Keep this and all drugs out of<br>the reach of children.</p>
<p>Manufactured by:<br>Orion Corporation<br>ORION PHARMA<br>Orionintie 1,<br>FIN-02200 Espoo, Finland.</p>
<p>Distributed by:<br>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">RM8303A1</span></p>
<div class="Figure">
<a name="id-1609268216"></a><img alt="Carbidopa, Levodopa and Entacapone Tablets 31.25 mg, 125 mg and 200 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4a535af2-16fc-4fdf-92ec-7941ef23a63a&amp;name=image-07.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_4606da57-516b-4052-aa7e-545e174a3316"></a><a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ 37.5 mg/150 mg/200 mg </h1>
<p class="First"><span class="Bold">NDC 0378-8304-01</span></p>
<p><span class="Bold">Carbidopa, Levodopa</span><br><span class="Bold">and Entacapone</span><br><span class="Bold">Tablets</span></p>
<p>Each film-coated tablet contains:<br>Carbidopa, USP . . . . . . 37.5 mg<br>Levodopa, USP . . . . . . . 150 mg<br>and<br>Entacapone . . . . . . . . . 200 mg</p>
<p><span class="Bold">Do not combine tablets to achieve a higher</span><br><span class="Bold">strength tablet due to the risk of entacapone</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
<p><span class="Bold">Rx onlyÂ Â Â Â Â 100 Tablets</span></p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">Dosage:</span>Â See package insert.</p>
<p>Swallow whole. Do not crush,<br>split, or chew.</p>
<p>Store at 25Â°C (77Â°F);<br>excursions permitted to<br>15Â°C to 30Â°C (59Â°F to 86Â°F).</p>
<p>[See USP Controlled Room<br>Temperature.]</p>
<p>Dispense in a tight container, (USP).</p>
<p>Keep this and all drugs out of<br>the reach of children.</p>
<p>Manufactured by:<br>Orion Corporation<br>ORION PHARMA<br>Orionintie 1,<br>FIN-02200 Espoo, Finland.</p>
<p>Distributed by:<br>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">RM8304A1</span></p>
<div class="Figure">
<a name="id1345063257"></a><img alt="Carbidopa, Levodopa and Entacapone Tablets 37.5 mg, 150 mg and 200 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4a535af2-16fc-4fdf-92ec-7941ef23a63a&amp;name=image-08.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_7f82f89a-42f5-47f7-9b3e-5eb97347e62e"></a><a name="section-21"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL â€“ 50 mg/200 mg/200 mg </h1>
<p class="First"><span class="Bold">NDC 0378-8305-01</span></p>
<p><span class="Bold">Carbidopa, Levodopa</span><br><span class="Bold">and Entacapone</span><br><span class="Bold">Tablets</span></p>
<p>Each film-coated tablet contains:<br>Carbidopa, USP . . . . . . 50 mg<br>Levodopa, USP . . . . . . . 200 mg<br>and<br>Entacapone . . . . . . . . . 200 mg</p>
<p><span class="Bold">Do not combine tablets to achieve a higher</span><br><span class="Bold">strength tablet due to the risk of entacapone</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
<p><span class="Bold">Rx onlyÂ Â Â Â Â 100 Tablets</span></p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">Dosage:</span>Â See package insert.</p>
<p>Swallow whole. Do not crush,<br>split, or chew.</p>
<p>Store at 25Â°C (77Â°F);<br>excursions permitted to<br>15Â°C to 30Â°C (59Â°F to 86Â°F).</p>
<p>[See USP Controlled Room<br>Temperature.]</p>
<p>Dispense in a tight container, (USP).</p>
<p>Keep this and all drugs out of<br>the reach of children.</p>
<p>Manufactured by:<br>Orion Corporation<br>ORION PHARMA<br>Orionintie 1,<br>FIN-02200 Espoo, Finland.</p>
<p>Distributed by:<br>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">RM8305A1</span></p>
<div class="Figure">
<a name="id-483011947"></a><img alt="Carbidopa, Levodopa and Entacapone Tablets 50 mg, 200 mg and 200 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4a535af2-16fc-4fdf-92ec-7941ef23a63a&amp;name=image-09.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARBIDOPA, LEVODOPA AND ENTACAPONEÂ 		
					</strong><br><span class="contentTableReg">carbidopa, levodopa and entacapone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-8300</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARBIDOPA</strong> (CARBIDOPA ANHYDROUS) </td>
<td class="formItem">CARBIDOPA ANHYDROUS</td>
<td class="formItem">12.5Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>LEVODOPA</strong> (LEVODOPA) </td>
<td class="formItem">LEVODOPA</td>
<td class="formItem">50Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ENTACAPONE</strong> (ENTACAPONE) </td>
<td class="formItem">ENTACAPONE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (brownish-greyish red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">STO;50</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-8300-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA021485</td>
<td class="formItem">02/12/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARBIDOPA, LEVODOPA AND ENTACAPONEÂ 		
					</strong><br><span class="contentTableReg">carbidopa, levodopa and entacapone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-8301</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARBIDOPA</strong> (CARBIDOPA ANHYDROUS) </td>
<td class="formItem">CARBIDOPA ANHYDROUS</td>
<td class="formItem">18.75Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>LEVODOPA</strong> (LEVODOPA) </td>
<td class="formItem">LEVODOPA</td>
<td class="formItem">75Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ENTACAPONE</strong> (ENTACAPONE) </td>
<td class="formItem">ENTACAPONE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (light brownish red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">STO;75</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-8301-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA021485</td>
<td class="formItem">10/28/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARBIDOPA, LEVODOPA AND ENTACAPONEÂ 		
					</strong><br><span class="contentTableReg">carbidopa, levodopa and entacapone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-8302</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARBIDOPA</strong> (CARBIDOPA ANHYDROUS) </td>
<td class="formItem">CARBIDOPA ANHYDROUS</td>
<td class="formItem">25Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>LEVODOPA</strong> (LEVODOPA) </td>
<td class="formItem">LEVODOPA</td>
<td class="formItem">100Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ENTACAPONE</strong> (ENTACAPONE) </td>
<td class="formItem">ENTACAPONE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (brownish-greyish red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">STO;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-8302-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA021485</td>
<td class="formItem">10/28/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARBIDOPA, LEVODOPA AND ENTACAPONEÂ 		
					</strong><br><span class="contentTableReg">carbidopa, levodopa and entacapone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-8303</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARBIDOPA</strong> (CARBIDOPA ANHYDROUS) </td>
<td class="formItem">CARBIDOPA ANHYDROUS</td>
<td class="formItem">31.25Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>LEVODOPA</strong> (LEVODOPA) </td>
<td class="formItem">LEVODOPA</td>
<td class="formItem">125Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ENTACAPONE</strong> (ENTACAPONE) </td>
<td class="formItem">ENTACAPONE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (light brownish red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">STO;125</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-8303-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA021485</td>
<td class="formItem">10/28/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARBIDOPA, LEVODOPA AND ENTACAPONEÂ 		
					</strong><br><span class="contentTableReg">carbidopa, levodopa and entacapone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-8304</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARBIDOPA</strong> (CARBIDOPA ANHYDROUS) </td>
<td class="formItem">CARBIDOPA ANHYDROUS</td>
<td class="formItem">37.5Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>LEVODOPA</strong> (LEVODOPA) </td>
<td class="formItem">LEVODOPA</td>
<td class="formItem">150Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ENTACAPONE</strong> (ENTACAPONE) </td>
<td class="formItem">ENTACAPONE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (brownish-greyish red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">STO;150</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-8304-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA021485</td>
<td class="formItem">10/28/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARBIDOPA, LEVODOPA AND ENTACAPONEÂ 		
					</strong><br><span class="contentTableReg">carbidopa, levodopa and entacapone tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-8305</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARBIDOPA</strong> (CARBIDOPA ANHYDROUS) </td>
<td class="formItem">CARBIDOPA ANHYDROUS</td>
<td class="formItem">50Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>LEVODOPA</strong> (LEVODOPA) </td>
<td class="formItem">LEVODOPA</td>
<td class="formItem">200Â mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ENTACAPONE</strong> (ENTACAPONE) </td>
<td class="formItem">ENTACAPONE</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (dark brownish red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">STO;200</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-8305-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA021485</td>
<td class="formItem">10/28/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ac6b2c1b-f828-4066-9cea-f07f3d02d878</div>
<div>Set id: 4a535af2-16fc-4fdf-92ec-7941ef23a63a</div>
<div>Version: 3</div>
<div>Effective Time: 20140731</div>
</div>
</div>Â <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
